Prevalence and factors associated with Attention Deficit Hyperactivity Disorder in Children and Adolescents with Epilepsy by Yogendra Singh,
1 
 
 
PREVALENCE AND FACTORS 
ASSOCIATED WITH ATTENTION 
DEFICIT HYPERACTIVITY DISORDER IN 
CHILDREN AND ADOLESCENTS WITH 
EPILEPSY 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertation submitted to 
                              The Tamil Nadu Dr.MGR Medical University 
                             In-part fulfillment of the requirement for  
         MD Branch XIX Psychiatry Final Examination to be held in May 2018 
 
2 
 
 
CERTIFICATE 
 
This is to certify that the dissertation titled ―PREVALENCE AND FACTORS 
ASSOCIATED WITH ATTENTION DEFICIT HYPERACTIVITY 
DISORDER IN CHILDREN AND ADOLESCENTS WITH EPILEPSY‖ is a 
bonafide work of Dr. Yogendra Singh in partial fulfillment of the 
requirements for the MD-Psychiatry (Final) examination of the TN Dr.MGR 
Medical University to be conducted in May 2018.   
 
 
 
 
Signature: 
Guide 
Dr. Priya Mammen 
Professor 
Child and Adolescent Psychiatry unit, 
Department of Psychiatry 
Christian Medical College 
Vellore 
3 
 
 
CERTIFICATE 
 
This is to certify that the dissertation titled ―PREVALENCE AND FACTORS 
ASSOCIATED WITH ATTENTION DEFICIT HYPERACTIVITY 
DISORDER IN CHILDREN AND ADOLESCENTS WITH EPILEPSY‖ is a 
bonafide work of Dr. Yogendra Singh in partial fulfillment of the 
requirements for the MD-Psychiatry (Final) examination of the TN Dr.MGR 
Medical University to be conducted in May 2018.   
 
 
 
 
 
Signature: 
Head of the Department 
Dr. Mary Anju Kuruvilla 
Professor and Head 
Department of Psychiatry  
Christian Medical College 
Vellore 
4 
 
 
CERTIFICATE 
 
This is to certify that the dissertation titled ―PREVALENCE AND FACTORS 
ASSOCIATED WITH ATTENTION DEFICIT HYPERACTIVITY 
DISORDER IN CHILDREN AND ADOLESCENTS WITH EPILEPSY‖ is a 
bonafide work of Dr. Yogendra Singh in partial fulfillment of the 
requirements for the MD-Psychiatry (Final) examination of the TN Dr.MGR 
Medical University to be conducted in May 2018.   
 
 
 
 
 
 
Signature: 
Principal 
Dr. Anna Pulimood 
Christian Medical College 
Vellore 
 
5 
 
 
DECLARATION 
 
I hereby declare that this dissertation titled ―PREVALENCE AND FACTORS 
ASSOCIATED WITH ATTENTION DEFICIT HYPERACTIVITY 
DISORDER IN CHILDREN AND ADOLESCENTS WITH EPILEPSY‖ was 
prepared by me in partial fulfillment of the regulations for the award of the 
degree of MD-Psychiatry of the TN Dr.M.G.R Medical University, Chennai.   
 
 
 
 
 
 
Signature: 
Dr. Yogendra Singh 
Post Graduate Registrar (MD) 
Department of Psychiatry  
Christian Medical College 
Vellore 
 
6 
 
ACKNOWLEDGEMENTS 
 
I am grateful to the Lord for helping and guiding me. 
I am grateful to the participants whom I recruited in the study for their co-
operation and patience. 
I especially thank my teacher and guide Dr. Priya Mammen for her support, 
guidance and constant encouragement. 
I especially thank my teacher and co-guide Dr. Paul S.S Russell for his 
support, guidance and constant encouragement. 
I especially thank my teacher and co-investigator Dr. Maya Thomas for her 
support, guidance and constant encouragement. 
I especially thank my teacher and co-guide Dr. Satya Raj for her support, 
guidance and constant encouragement. 
My sincere thanks to Ms.Visalakshi, my statistician, for her help and 
guidance in the analysis of the data. 
My sincere thanks to Dr. Sherab Tsheringla, Ms. Sushila Russell, Dr. 
Shonima Raj, Ms. Merlin Thanka, Dr.Stephan A Jiwanmall and Dr. Sanmitra 
Dasgupta for their valuable help. 
7 
 
I thank all my colleagues, friends and professors for their help, support and 
constant concern. 
I thank the Neurology division of Department of Neurological Science, 
Christian Medical College, Vellore for permitting me to undertake this study 
in Paediatric Neurology Clinic. 
I thank the Principal and the management of Christian Medical College, 
Vellore for permitting me to undertake this study. 
 
 
Dr. Yogendra Singh 
8 
 
 
 
9 
 
 
 
10 
 
 
 
11 
 
 
 
12 
 
 
 
13 
 
INDEX 
 
CHAPTER        PAGE 
I. INTRODUCTION                                                    14 
 
II. REVIEW OF LITERATURE                                 17 
 
III. AIMS & OBJECTIVES                                           50 
 
IV. METHODOLOGY                                                   51 
 
V. RESULTS                                                                  60 
 
VI. DISCUSSION                                                            83 
 
VII. SUMMARY                                                               90 
 
VIII. BIBLIOGRAPHY                                                     92 
 
IX. APPENDICES                                                           104 
 
 
 
 
 
 
 
 
 
 
14 
 
I.INTRODUCTION 
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder 
characterized by an ongoing pattern of difficulty paying attention, increased activity 
and impulsivity, which is not appropriate for age and interferes with functioning 
and overall development.  
Attention deficit hyperactivity disorder (ADHD) is one of the most common 
neuropsychiatric disorders of childhood and adolescence.  
British pediatrician Sir George Frederick Still first described ADHD in 1902 as ―an 
abnormal defect of moral control in children‖. In past, ADHD was labeled with 
multiple terms like minimal brain damage, minimal brain dysfunction, Kramer-
Pollnow syndrome, hyperkinetic syndrome or hyperactivity.  
Diagnostic and Statistical Manual (DSM) of Mental Disorders was first published in 
1952, had no mention of ADHD. The second edition released in 1968 included 
hyperkinetic impulse disorder for the first time.  
As per DSM-5, it can be manifested in any of 18 official symptoms. It can be full-
expression (combined type) or partial expression (inattentive or hyperactive-
impulsive types). To qualify for the diagnosis, six of the nine inattentive symptoms 
are required for the diagnosis of the inattentive type and six of the nine hyperactive-
impulsive symptoms are required for the diagnosis of hyperactive-impulsive type, 
with six of each list for the combined type. 
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 Various studies have concluded that the ADHD subtypes provide current levels of 
inattention and hyperactivity-impulsivity symptoms, but are not sufficient to justify 
the classification of distinct forms of the disorder in long-term.  
The ADHD worldwide prevalence ranges from 5.29% to 7.2% in children and 
adolescents. A various study conducted in India also document the prevalence in the 
same range. In India, a systemic review and meta-analysis estimate the prevalence 
of ADHD to be 6.46%. Most of the children diagnosed with ADHD continue to 
meet criteria for ADHD as adults. 
Despite multiple studies, the etiology and pathogenesis of ADHD are not clear. This 
complex disorder is the outcome of both environmental and genetic factors. Various 
adoption, twins and molecular genetic studies support the theory of ADHD being a 
familial disorder.   
ADHD has been observed to be comorbid with a variety of psychiatric disorders 
which include oppositional defiant, conduct, affective, anxiety, and learning 
disorders.  
Various studies and through the clinical experiences, it is clear that Attention 
Deficit Hyperactivity Disorder is found in a higher percentage of the pediatric 
population with Epilepsy. In one multivariate analysis, children with ADHD had 
almost twice the risk of Epilepsy than children without ADHD. This study supports 
findings of a strong interrelationship between ADHD and Epilepsy.  Disorders of 
attention may be the most frequent behavioral problems in children with Epilepsy. 
As found in different studies the prevalence of Attention Deficit Hyperactivity 
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Disorder in children and adolescents with Epilepsyrange from 20% to 38%.Children 
and adolescents with unprovoked seizures were found 2.5 fold more likely to have a 
history of attention deficit hyperactivity disorder in one study. It was also shown 
that age of onset of attention deficit hyperactivity disorder was earlier in pediatric 
age group with Epilepsy as compared to without Epilepsy. 
Attention Deficit Hyperactivity Disorder and Seizures may be comorbid conditions. 
That is, the two disorders may occur together owing to a causal relationship 
between them or owing to an underlying vulnerability to both disorders. Both the 
disorder effect each other in terms of distribution in gender and age of onset, in 
terms of medicine used for treating them and current control of symptoms. There 
are multiple variables affecting the association between these two illness. They need 
to be studied. It has been shown that attention deficit hyperactivity disorder and 
Epilepsy can individually effect the learning, social and behavioral development of 
children. As such these been comorbid in high percentage is expected to have a 
greater implication on children development in all aspects.  Such hyperactivity and 
appropriate treatment of these problems might improve the scholastic performance. 
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II.REVIEW OF LITERATURE 
II.a. Attention Deficit Hyperactivity Disorder in Children: 
Attention Deficit Hyperactivity Disorder (ADHD) is diagnosed in children with a 
significant problem in maintaining attention, an excessive activity typically with 
impulsivity and all of this not appropriate for the age. The presentation is rather 
heterogeneous with variability in the severity of symptoms, the age of onset, 
dysfunction due to symptoms and comorbid psychiatric disorders associated.  
It is one of the most common neuropsychiatric disorder for which children are 
referred to psychiatric support. 
II. a. 1.  History  
Initial references of ADHD dates back to mid nineteen century in the poetry named 
as ―Fidgety Phil‖ written by German physicians Heinrich Hoffman(1). These 
poetries were his experiences in medical practice. But the credible scientific focus 
was first given by Sir George Still in 1902 and he presented 43 cases of children 
with problems in sustained attention, which he picked from his clinical practice. He 
believed that these children have a defect in ―moral control of behavior‖(2). He 
observed that these children were often aggressive, resistant to discipline, non-
obeying and emotional. He concluded that the impairments can be due to a defect of 
cognitive relation to the environment, inhibitory volition or moral consciousness. 
It was observed that various brain diseases like birth trauma, lead toxicity, Epilepsy, 
head trauma and infections manifested as numerous cognitive impairments and 
behavioral symptoms which resembled ADHD symptoms. Terms like ―Restlessness 
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syndrome‖(3)  and ―organic drivenness‖ (4)was being used for such manifestations. 
Several investigators postulated that these symptoms are the result of pathological 
defects in the brain structure although gross evidence may not be apparent always. 
Taking into consideration that no clear evidence of brain damage was found, a new 
concept on ―minimal brain dysfunction‖ emerged. But, serious questions were 
raised for such concept as no historical documentation of brain damage was present 
in such cases. On the other hand, special educational recommendations were made 
for such brain-damaged children(5), which continues to be a forerunner in current 
educational plans for ADHD children, even though it lacks scientific support. 
In a period from 1935 to 1945 multiple papers appeared which marked the 
beginning of pharmacological management of these disorders. First being 
Amphetamine, showed significant improvements.By 1970 stimulants medication 
became the treatment of choice. 
In the 1950s, writers started using term ―hyperkinetic impulse disorder‖ for ADHD 
and a number of investigations were done for understanding the neurological 
mechanism resulting in these behavioral symptoms. They believed that the central 
nervous system deficit occurred in the thalamic area, where the stimulations were 
not adequately filtered and thus led to increased stimulation of the brain. These 
were supported by a study of the effects of ―photo-metrol‖ method(6).Others studies 
at same period showed that imbalance between cortical and subcortical areas of the 
brain was the cause of these behaviors. The diminished control of subcortical areas 
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permitted overstimulation of cortex(7). So it was clear that concept of brain damage 
syndrome as a cause of hyperactivity was well accepted till that period. 
But in the 1960s the validity of the concept of brain damage in children with such 
behavior was questioned again. It was eventually recognized as vague, over-
inclusive and without much neurological evidence. 
As the dissatisfaction for the term ―minimal brain dysfunction‖ grew, the emphasis 
was shifted to most characteristic behavior symptom that is hyperactivity. Thus lead 
to the concept of hyperactivity syndrome. 
Chess defined the hyperactive children as those who carry out activities at a higher 
speed than normal rate as of the average child or who are continuously in motion, or 
both. Chess emphasized activity as the defining feature of the disorder rather than 
underlying neurological causes. He stressed to consider objective evidence of the 
symptom beyond the subjective reports of others, took the blame away from the 
parents and separated the syndrome of hyperactivity from the brain damage 
syndrome(2). It was now recognized that hyperactivity was a behavioral syndrome 
that can arise from organic pathology, but not necessary.  
The American Psychiatric Association (APA) did not recognize ADHD in the first 
edition of Diagnostic and Statistical Manual of Mental Disorder (DSM). The second 
edition DSM was published in 1968. This edition included hyperkinetic impulse 
disorder for the first time and described the disorder as characterized by over-
activity, restlessness, distractibility, and short attention span, especially in younger 
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children which usually diminishes by adolescence(8). It took the lead of Chess and 
stressed that the disorder was developmentally benign. 
In the early 1970s, the defining features of hyperactivity were broadened to include 
impulsivity, short attention span, low frustration tolerance, distractibility, and 
aggressiveness(9). 
At the start of the 1970s, Wender described the essential psychological 
characteristics of children with minimal brain dysfunction as consisting of motor 
behavior, attention and perceptual-cognitive functioning, learning, impulse control, 
interpersonal relations, and emotion. But later it was realized that 
Wender was combining the symptoms of oppositional defiant disorder and conduct 
disorder with those of ADHD to form a single disorder. Sufficient evidence, 
however, shows that ADHD and ODD are not the same disorder. 
By early 1990s it was highly supported that hyperactivity was not caused by brain 
damage. It was advocated that true brain damage did not display a uniform pattern 
of behavioral deficits and children with hyperactivity rarely had evidence of 
neurological damage. 
The exclusive focus on hyperactivity as the only characteristic symptom of this 
disorder was always questioned (10). Virginia Douglas in 1972 argued that deficits 
in sustained attention and impulse control were more likely than just hyperactivity 
to account for the difficulties faced by ADHD children. Douglas observed that 
hyperactive children did not necessarily have more learning disabilities, auditory or 
right–left discrimination problems or difficulties with short-term memory as 
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compared to other children(11). Douglas and Susan Campbell demonstrated that 
hyperactive children were not always more distractible and that the sustained 
attention problems could emerge without significant distractions in the 
environment. Gabrielle Weiss in her follow-up studies observed that although the 
hyperactivity often diminished by adolescence, poor sustained attention and 
impulsivity persisted. Douglas research work leads the disorder being renamed 
Attention Deficit Disorder (ADD), with or without Hyperactivity in 1980 with the 
publication of DSM-III(American Psychiatric Association, 1980)(12).In this 
revision deficits in sustained attention and impulse control were given more 
significance in the diagnosis than hyperactivity. This was supported by growing 
evidence that hyperactivity was not specific to this particular condition, that the 
symptoms were quite situational and that there was no clear delineation between 
normal and abnormal levels of activity. The DSM-III diagnostic criteria was 
noteworthy not only for their greater emphasis on inattention and impulsivity but 
also for much more specific symptom lists. In the next revision DSM-III-R 
(13)(American Psychiatric Association, 1987), the criteria for only the diagnostic 
criteria for ADD with Hyperactivity were stipulated. ADD without hyperactivity 
was relegated to a minimally defined category. In DSM-IV released in 1994 (14)the 
diagnosis was slipped into three subtypes, ADHD inattentive type, ADHD 
hyperactive-impulsive type and ADHD combined type. These terms were continued 
in the DSM-5 released in 2013(12) In 1937, psychiatrist Charles Bradley 
administered Benzedrine sulfate, an amphetamine, to ―problem‖ children at the 
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Emma Pendleton Bradley Home in Providence, Rhode Island, in an attempt to 
alleviate headaches; however, Bradley noticed an unexpected effect upon the 
behavior of the children: improved school performance, social interactions, and 
emotional responses. 
 
In 1937, psychiatrist Charles Bradley administered Benzedrine sulfate, an 
amphetamine, to children with a behavior problem in an attempt to alleviate 
headaches caused by performing pneumoencephalograms. He was working at the 
Emma Pendleton Bradley Home in Providence, Rhode Island at that time. Bradley 
observed an improvement in school performance, social interactions, and emotional 
responses in these children(15). Bradley was surprised at this unexpected effect 
especially for a drug known to be a stimulant. It should be noted, however, that the 
higher levels of the central nervous system have inhibition as their function, and 
that stimulation of these portions might indeed reduce activity(16). Bradley‘s 
observations of stimulant effects were revolutionary. 
Methylphenidate was first synthesized in 1944 by Leandro Panizzon is a piperazine 
substituted phenylisopropylamine that is traditionally related to amphetamine. It 
was initially used in the treatment of chronic fatigue, lethargy, depressive states, 
psychosis associated with depression and narcolepsy, but it‘s most impressive effect 
has been the reduction of symptoms of ADHD. Methylphenidate is regarded by 
now as the most effective psycho-stimulant and used for ADHD management 
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II.a. 2. Primary symptoms 
Inattention: 
By definition, children and adults who have ADHD display difficulties with 
attention relative to normal children or other control groups of the same age and 
gender. Though critics of ADHD point that these are just subjective opinions having 
no reality Studies on contrary to this, using direct observations of child behavior 
find that off-task behavior or poor attention to work is recorded significantly more 
often for children and adolescents with ADHD as compared to those with learning 
disabilities or without disabilities(17). The construct of attention is 
multidimensional and include alertness, arousal, selective focus, sustained attention, 
and distractibility(18). ADHD is not associated with significant difficulties with 
automatic orienting to visual information, mediated by posterior brain attention 
circuits(19) Instead, children and adolescents with ADHD face difficulty sustaining 
their attention to tasks(20). Distractibility is other problem behavior, which is the 
likelihood of responding to the occurrence of extraneous events unrelated to the 
task. This symptom is significantly elevated in ADHD. Distractors within the task 
will be more disruptive than those outside the task. Distractibility depends on the 
cognitive loading or difficulty of the task. The attention appears to be diminished 
persistence of effort or sustained responding to tasks that have the little intrinsic 
appeal or minimal immediate consequences for completion. Such children spend 
much more time engaged in off-task. In another subset of children with ADHD, 
predominantly inattention type manifest as hypo-activity, lethargy, and 
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daydreaming. Evidence suggests that there are two distinct dimensions of 
inattention. The first dimension is well established set of inattentive symptoms and 
primarily reflecting distractibility. The second dimension reflects a more day-
dreamy quality, more passive and lethargic in form.  
Impulsivity and Hyperactivity: 
The second dimension of symptoms is poor inhibition and associated hyperactivity 
(21). Patients with ADHD respond quickly without waiting for instructions to be 
completed or adequately appreciating the situation, as a result, end up doing 
careless errors. They fail to judge the potentially negative, destructive, or even 
dangerous consequences of their behaviors and thus often engage in unnecessary 
risk-taking. Consequently, accidental poisonings and injuries are common 
presentations. They may carelessly damage or destroy property.  As result of 
aforesaid behavior, they are considered to be one with poor self-control, 
irresponsible, immature, lazy, and rude due to which these children often experience 
punishment, criticism, and censure. 
Impulsivity is multidimensional in nature (22). It involves constructs of executive 
control, delay of gratification, effort, even compliance, motivation, and automatic 
attention inhibitory processes. ADHD involves the poor executive functioning and 
sustained inhibition. Patient is unable to delay a response or defer gratification(23) 
Children with ADHD have problem with delay aversion, that is they find waiting to 
be aversive, and hence act impulsively to terminate the delay((24) 
25 
 
A lot of authors believed that poor effortful regulation and inhibition of behaviors, 
in fact, the hallmark of ADHD(25). They noticed that inattention does not 
distinguish children with ADHD from those with other clinical disorders or normal 
children. On the other hand hyperactivity, impulsivity, disinhibition, and poor 
regulation of behaviors are stronger in distinguishing them. The discriminant-
function analysis showed that the symptoms of impulsive error and excessive 
activity level best discriminate children with ADHD from those without ADHD 
(26). Similar supportive evidence was derived from the field trial of the DSM-III-R 
symptom list which revealed that symptoms characteristic of dis-inhibition, such as 
poorly regulated activity and impulsivity, were more likely to discriminate children 
with ADHD from those without. The evidence available is sufficient to conclude 
that behavioral dis-inhibition is the hallmark of ADHD and not inattention. Studies 
have also suggested that there is a higher incidence of ADHD among biological 
relatives of children with ADHD who have significant problems with 
inhibition(27). 
Hyperactivity: Children with ADHD are shown symptoms of excessive or 
developmentally inappropriate higher levels of activity, which can be motor or 
vocal. They present with Restless-ness, fidgeting, and unnecessary gross bodily 
movements commonly, as reported by parents and teachers and in objective 
measures. These excessive movements are often not relevant to the task or situation, 
and often seem to have no purpose. Numerous scientific studies using Objective 
measures of activity level used in various studies show that children with ADHD 
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are more active, restless, and fidgety throughout the day and even during sleep, as 
compared to normal children (28). Measures based on ankle movement, 
locomotion, wrist activity and total body motion seem to differentiate them from 
nondisabled children.(29) Objective measurement of activity level during tasks 
requiring sustained attention reveals that these children move their heads and bodies 
more than normal ones. These children move further away from their chairs and 
cover a greater spatial area in doing so. Their movement is more complex in the 
pattern(30). It was also observed that overall symptoms fluctuated significantly with 
the situation(31). They fail to regulate their activity level to setting or task demands 
which is socially problematic in addition to just increased absolute level of 
movement. There is some evidence that these symptoms at times increase in 
frequency in under-stimulating environments and decrease when stimulation is 
added to the situation, and thus hyperactivity can be a form of stimulations. (32) 
Some authors believe that the pervasiveness of the hyperactivity across different 
settings is important for diagnosing ADHD. While the others believe that the 
distinction may have more to do with the sources of information than situational 
pervasiveness(33).  
As noted earlier in the various articles that hyperactivity-impulsivity rather than 
inattention, that best distinguishes ADHD from other clinical conditions and from 
normal children. Hence, a greater weight can probably be given to the impulsive–
hyperactive behavior characteristics than to inattention in clinical delineation(2).  
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Adults with ADH present mostly with the difficulties with fidgeting, a subjective 
sense of restlessness, and excessive speech, in comparison with children who 
present with more gross motor over-activity characteristic. 
II.a. 3. Cognitive and Developmental Problems with ADHD: 
Children with Attention-Deficit Hyperactivity Disorder besides facing the core 
symptoms of inattention, impulsivity, and over-activity may have a variety of other 
difficulties. They have higher chances of having other cognitive, developmental, 
academic, and health-related problems. Though all such children do not show such 
problems, ADHD children show a higher prevalence of these problems than 
expected in typical children. 
 
 
Intellectual Development: 
Children with ADHD show poor intellectual performance as compared to either 
normal children or their own siblings do on standardized intelligence tests (34). 
This association is stronger in children than adults but even in adults is significant 
(35). Despite this association between intellectual deficit and ADHD, children with 
ADHD are likely to represent the entire spectrum of intellectual development. 
The impairment in behavioral inhibition and executive functioning in children with 
ADHD could be an explanation for the inverse relationship between ADHD and IQ. 
Intelligence depends on executive functions of working memory, internalized 
speech, and verbal thought developed and all of these are disturbed in ADHD. It 
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was observed in various studies that both normal children and children with 
behavioral problems have significant negative associations between hyperactive-
impulsive behavior and measures of intelligence. But no such clear associations had 
been found between conduct problems and intelligence (36).Thus suggesting that 
the hyperactive-impulsive element of the disruptive behavior can be attributed to 
the inverse relationship between IQ and disruptive behavior in children. 
IQ studied in children with ADHD and their normal siblings suggest that ADHD 
has an inherent association with diminished IQ (37). 
Adaptive Functioning: 
It refers to the actual performance of the daily activities which are required to fulfill 
personal and social needs. Several studies have consistently documented deficits in 
adaptive functioning in children with ADHD explaining poor long-term prognosis, 
suggesting the need for assessment and treatment of adaptive functioning in such 
children(38). Children with ADHD generally have average intelligence but often 
function in the low-average to a borderline range of adaptive functioning. Such a 
disparity probably reflects a discrepancy between ability and performance.  As 
compared to other psychiatric and developmental disorder, children with ADHD 
show a greater discrepancy between adaptive functioning and IQ. Other supportive 
studies report that the adaptive functioning in the children with Pervasive 
Developmental Delay or Intellectual Disability, or normal children were observed 
to be relatively consistent with their level of intelligence. Other studies reported that 
comorbid learning disabilities and behavior problem does not seem to significantly 
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affect this disparity.A separate study shows poorer adaptive communication skills 
associated with ADHD relative to Oppositional Defiant Disorder or Conduct 
Disorder, or normal children. 
Academic Performance:  
Most of the children with ADHD are doing poorly at school. Their performance is 
low relative to their known levels of ability, which is believed to be due to their 
inattentive, impulsive, and restless behavior in the classroom. Multiple studies 
demonstrate significant improvements in academic performance when children with 
ADHD are on stimulant medication(39). This can be accepted as evidence that 
children with ADHD have a poor academic performance by the virtue of disorder 
itself. Children with ADHD are also likely to show performances on various 
standardized achievement tests.(40) These deficits may include reading, arithmetic, 
spelling, and comprehension. A meta-analysis concluded that ADHD is associated 
with large decrements in academic performance(34). 
While other studies demonstrate that it is associated decrements in intelligence 
which account for scholastic underachievement and not the conduct problems that is 
often seen in children with ADHD(41). Due to the deficit in the academic skills, a 
huge percentage of children with ADHD require academic tutoring, repeat a grade 
in school, are placed in special education programs, are suspended from school, or 
drop out school (42). 
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Specific Learning Disabilities:  
Children with ADHD are more likely than normal children to have Specific 
Learning Disabilities. Due to inconsistencies in the criteria used to define Learning 
Disability, the prevalence of Learning Disability in different studies is highly 
variable. Using a liberal definition of Learning Disability, 38% of Children with 
ADHD were found to have it as compared to 8% in normal children(43).  
Speech and Language Development:  
Children with ADHD do not present with serious or generalized language delays. 
Various contradicting studies cannot confirm whether there is a delay or not. They 
present with a specific problem in speech development, for example, expressive 
language problems are more common than receptive language. On the other hand, a 
huge percentage of children with speech and language disorder can be diagnosed 
with ADHD. Children with ADHD are more talkative than normal children when 
conversing spontaneously(44). But they are poor in organizing and generating 
speech in response to specific task demands. In such situation, they talk less and are 
more nonfluent(45). Confrontational speech or explanatory speech is more difficult 
as it involves careful thought and organization. Children with ADHD have 
problems in the cognitive processes involved in organizing and monitoring thinking 
and thus lead to aforesaid speech problems. 
Evidence of thought disorder is present in both the children with ADHD and those 
with schizophrenia, but ADHD group have less severe thought disorder than the 
group with schizophrenia. Children with Schizophrenia show greater illogical 
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thinking, less cohesion, and greater loose associations as compared to children with 
ADHD.  
Accidental Injuries: 
 Children with ADHD are found to be more prone to accidents than are typical 
children(46). But it was observed that these children do not lack knowledge of 
safety or accident prevention(47). In spite of no deficiencies in knowledge of 
driving, safety, and accident prevention, young adults with ADHD have 
significantly more motor vehicle accidents(48). 
Delay in internalization of Speech: 
Children with ADHD are to be less mature in their self-speech and developmentally 
delay in the progression from public to private self-speech(49). All children show a 
similar sequence of development of private speech, but Children with ADHD show 
a considerable delay in this process relative to other children.  
Greater Variability of Task Performance: 
Children with ADHD show the excessive variability of task or work performance 
over time. Their standard deviation of performance on multiple trial tasks is 
considerably larger than that of normal children(50). The number of tasks they 
complete and the accuracy of their performance changes significantly from trial to 
trial in the same setting. Teachers often report much greater variability in 
homework and in-class performance, than seen in other children. Parents report 
these children perform certain chores swiftly and accurately at one time while 
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slowly on other time. No gender difference was noted for the above phenomenon 
for the various tasks in performance tests(50). 
 
Memory and Planning Difficulties: 
Nonverbal Working Memory 
The nonverbal working memory includes visual-spatial working memory, 
sequential working memory and the sense of time.  
Children with ADHD generally do not show a deficit in the recall, long-term 
storage, and long-term retrieval(40). But in the standard test evaluating working 
memory, these children document significant deficits. 
Studies on visual-spatial working memory in children with ADHD are limited and 
present with conflicting results. 
Studies of hand movement sequences document a deficit, while those involving 
trail-making sequences revealed no deficit. 
Multiple studies show that sense of time is impaired in children with ADHD. The 
sense of time in ADHD children does not seem to improve with a stimulant(51). 
Verbal Working Memory 
Children with ADHD face difficulty in mental computation and are less efficient 
than normal children (52). Meta-analysis of nine studies using a mental arithmetic 
test reported similar statistically significant finding. Thus it is evident that verbal 
working memory as assessed by mental computation is impaired in children with 
ADHD. 
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Children and adolescents diagnosed with ADHD have shown difficulties with digit 
span. The Freedom from Distractibility factor of The Wechsler Intelligence Scale 
for Children-Revised comprises tests of digit span, mental arithmetic, and coding. It 
reflects the executive processes, on which the children with ADHD perform more 
poorly than normal children(53). Multiple studies, although, support that ADHD is 
associated with deficits in verbal working memory, learning disabilities can be often 
a confounding factor for this deficit. 
The storage and recall of simple information on verbal memory tests have been 
found to be intact in children with ADHD (40). The deficit is evident when large 
and complex amounts of verbal information had to be retained over a lengthy 
period. These children require more proficient strategies that assist with organizing 
material to respond and remember effectively. It has also been demonstrated in 
adults with ADHD. 
Hindsight, Forethought, and Planning: 
Children with ADHD find difficult to adjust their subsequent responses based on an 
immediately past incorrect response(54). These children often fail to use the 
warning stimulus to prepare for the upcoming response trial and take longer 
preparatory intervals. Their capacity to create and maintain an anticipatory 
preparation for an impending event has also been shown to be impaired. 
Along with these children and adolescents face problems in arousal and may have 
minor sleep difficulties. Studies support minor physical anomalies in this 
population. 
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ADHD is associated with emotion regulation. They display a higher level of anger 
and frustration. 
Though primary sensory difficulties are not evident, motor development difficulties 
are common. 
And the last, it is observed that children and adolescents with ADHD show greater 
medical care utilization and medical costs. 
Multiple neuropsychological examinations which assess the construct of planning 
like the Tower of Hanoi (TOH), found children with ADHD to perform more poorly 
as compared to normal nondisabled children.  
Children with ADHD shown deficit in performance tests like maze test and six 
elements test which assess planning. 
II. a. 4. Prevalence of ADHD 
The worldwide prevalence estimates of ADHD are highly heterogeneous due to 
poorly understood reasons. It could be due to non-uniform diagnostic criteria, a 
different source of information, the requirement of impairment for diagnosis, and 
various geographic origin of the studies.  
The ADHD worldwide pooled prevalence was 5.29% in one of systemic review and 
meta-regression analysis(55), an another comprehensive meta-analysis estimated  
the prevalence of attention deficit hyperactivity disorder (ADHD) 5.9–7.1 % based 
on DSM-IV criteria (56), while another  systematic review and meta-analysis 
showed an overall pooled prevalence estimate of 7.2% in  children and 
adolescents(57).  
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In India, a systemic review and meta-analysis estimate the prevalence of ADHD to 
be 6.46%(58). 
Most of the children diagnosed with ADHD continue to meet criteria for ADHD as 
adults(59). 
There is clear gender difference with respect to the prevalence of ADHD and its 
presentation. The male-to-female ratio between clinic-referred and community 
samples of children with ADHD can be 10:1 and 3:1 respectively. Few studies 
observe that this huge difference can be explained by the referral bias as boys are 
referred due to more disruptive behavior than girls. 
In one study the ADHD prevalence ratio for males versus females was estimated to 
be 2.28:1, lower than the usually accepted estimate of 4:1 on an average. Since the 
study was based on a population-based sample, results were not subject to clinical 
referral bias that can lead to under-representation of females. It was also observed in 
the same study that though the overall prevalence of ADHD decreases with age, the 
ratio between males and females remains relatively stable(60). 
It was observed that the gender prevalence gap was more in referred or clinical 
sample than non-referred.  A study with small sample size on a non-referred group 
of ADHD subjects showed that gender did not influence ADHD-associated 
morbidity and dysfunction and that both genders were associated with high levels of 
psychiatric comorbidity and psycho-educational dysfunction(61). 
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Various studies have concluded that the ADHD subtypes provide current levels of 
inattention and hyperactivity-impulsivity symptoms, but are not sufficient to justify 
the classification of distinct forms of the disorder in long-term(62).  
II.a.5. Diagnostic Criteria 
Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)(12) 
The American Psychiatric Association has defined criteria for the diagnosis of 
ADHD, published in the Diagnostic and Statistical Manual of Mental Disorders 
Fifth Edition (DSM-5) [1].  
The salient feature of the criteria includes: 
1. For a diagnosis in children <17 years, a minimum of ≥6 symptoms of 
hyperactivity and impulsivity or ≥6 symptoms of inattention are required.  
2. For a diagnosis in adolescent ≥17 years and adults, a minimum of ≥5 
symptoms of hyperactivity and impulsivity or ≥5 symptoms of inattention 
are required.  
3. Symptoms must be often present 
4. Symptoms must be present in more than one setting. 
5. Should persist for a minimum period of six months 
6. Should be present before the age of 12 years 
7. Impair function in academic, social, or occupational activities 
8. Be excessive for the developmental level of the child 
9. Other physical, situational, or mental health conditions that could present 
with similar for symptoms should be excluded 
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These diagnostic criteria have high inter-rater reliability. These criteria do not over-
diagnosis or misdiagnosis of ADHD(63).  
Depending upon the predominant symptoms, ADHD can be categorized into one of 
the three subtypes which are predominantly inattentive, predominantly hyperactive-
impulsive, and combined type.  
These subtyping of a given patient can change from one to another over time(64). 
Limitations include the derivation of criteria from studies of children evaluated in 
the psychiatric special clinic rather than primary care setting. Moreover, the 
requirements of symptoms presenting before the age of 12 years are controversial. 
International Classification of Mental and Behavioural Disorders 10th revision 
(ICD-10)(65).  
This medical classification system was published by the World Health Organization 
(WHO) in 1992. 
ICD-10 refers to attention-deficit hyperactivity disorder (ADHD) as hyperkinetic 
disorder (HKD). 
This classification system defines Hyperkinetic Disorder as a persistent and severe 
impairment of psychological development, characterized by early onset of 
overactive, marked inattention and lack of persistent task involvement which are 
pervasive over situations and persistent over time.  
Salient features of the ICD-10 medical classification system for ADHD: 
i. The main symptoms of HKD are impaired attention and over-activity.  
ii. Both are necessary for diagnosis 
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iii. Behavioural symptoms should present prior to 6 years of age and continue 
for long duration 
iv. Impairment must be present in two or more settings (e.g. home, classroom, 
clinic) 
v. Diagnosis of anxiety disorders, mood affective disorders, pervasive 
developmental disorders and schizophrenia must be excluded.  
vi. The diagnosis should only be considered if symptoms are excessive for the 
child‘s age and Intelligence quotient, and are abnormal in the context of what 
is expected in the  specified situation 
ICD-10 also lists symptoms characteristic of children with HKD, which are not 
required for making a diagnosis.These include disinhibited in social relationships, 
recklessness in dangerous situations and non-adherence to social norms 
II.a.6. Comorbid Disorders 
Clinical observation and multiple studies noted that Attention Deficit Hyperactivity 
Disorder (ADHD) has been comorbid with a variety of psychiatric disorders. These 
include behavioral disorder like oppositional defiant and conduct disorders, as well 
as the affective disorders, anxiety disorders, and learning disorders(43,66).  
The reason of such high overlap continues to be a query. Not only there is a 
combination of symptoms in the event of comorbidity, the overall course and 
prognosis at times are affected. For example, ADHD and ADHD with conduct 
disorder appear to be distinct subtypes. Children with ADHD and conduct disorder 
children have higher rates of antisocial personality as adults, though the short-term 
39 
 
response to stimulants is the same as in children with ADHD only. Similarly, the 
stimulant response is poorer in ADHD children with comorbid anxiety, though 
impulsivity is attenuated in ADHD in such children. Regardless of prevalence, 
children with ADHD and aforesaid comorbidities have high rates of aggression and 
psychiatric disorder in their families.  
II. a. 7. Treatment Options. 
Treatment options include the pharmacological interventions, the non-
pharmacological intervention, or a combination of aforesaid options.  
Initially, the studies focused on the short-term trial of medication and psychological 
interventions for the treatment of ADHD. 
Introduction of stimulants for ADHD was observed to be very promising. Analog 
classroom setting examined hour to hour effects of medication on behavior and 
cognition which helped in the further development of other stimulants. 
This was followed by multiple large studies which were conducted to study the 
properties of these stimulants along with efficacy of atomoxetine and 
methylphenidate transdermal patch(67,68). 
The beneficial effect of psychosocial interventions in the management of ADHD 
had also been proved in various effect. 
The Multimodal Treatment Study of ADHD (MTA) was started to look at the 
effects of medication management, behavior modification therapy and their 
combination, and usual community comparison in the treatment ADHD over a long 
period. The 14-month assessment showed the superiority of the medical 
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management or combination therapy over behavior modification therapy and 
community comparison.It also reported modest benefits of combination therapy 
over medical management alone. Re-evaluation after further 10 months showed 
persisting same finding but the gap was reduced(69).  
II.b.Epilepsy in Children 
Epilepsy is a disorder of the brain characterized by an enduring predisposition to 
generate epileptic seizures. The International League Against Epilepsy (ILAE) task 
force deﬁned Epilepsy if at least two unprovoked (or reﬂex) seizures occurring >24 
h apart, or one unprovoked (or reﬂex) seizure and a probability of further seizures 
similar to the general recurrence risk (at least 60%) after two unprovoked seizures, 
occurring over the next 10 years, or in case of diagnosis of an Epilepsy 
syndrome(70). 
World Health Organization estimates that approximately 50 million people 
currently live with Epilepsy worldwide. Between 4 and 10 per 1000 people of the 
general population are estimated to have active Epilepsy at a given time.  
The incidence of Epilepsy in children ranges from 41-187/100,000, but the 
prevalence of Epilepsy in children is consistently higher.  It ranges from 3.2-
5.5/1,000 in developed countries as compared to 3.6-44/1,000 in underdeveloped 
countries(71).  
It was noted that prevalence was higher in rural areas as compared to urban areas. 
Moreover, the incidence of Epilepsy is consistently reported to be highest in the 
first year of life and it declines to adult levels by the end of the first decade of life. 
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Emotional, behavioral, and relationship difficulties are more prevalent in children 
with Epilepsy. They constitute a significant burden to the children and their 
families(72). 
The children with Epilepsy make less academic progress than expected for their age 
and Intelligence level. The academic performance of these children depends on the 
age of the child, age of seizure onset, lifetime total seizure frequency, and presence 
of multiple seizures(73). 
II.c. Attention Deficit Hyperactivity Disorder in Children with Epilepsy 
II.c.1. Introduction 
The association between ADHD and Epilepsy has been the topic of several studies. 
ADHD and Epilepsy may be comorbid conditions. That is, the two disorders may 
occur together owing to a causal relationship between them or owing to an 
underlying vulnerability to both disorders. Both the disorder effect each other in 
terms of distribution in gender and age of onset, in terms of medicine used for 
treating them and current control of symptoms. There are multiple other variables 
affecting the association between these two illness. They need to be studied. It has 
been shown that attention deficit hyperactivity disorder and Epilepsy can 
individually effect the learning, social and behavioral development of children. As 
such these been comorbid in high percentage is expected to have a greater 
implication on children development in all aspects.  Such children are at known risk 
for academic underachievement which can be due to inattention and hyperactivity, 
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and appropriate treatment of these problems might improve the scholastic 
performance. 
II.c.2. Clinical Presentation 
The clinical presentation in ADHD children with Epilepsy is variable in view of the 
complexity of this combination. Both ADHD and Epilepsy can independently affect 
the neuropsychological process. Studies have shown that children with complex 
partial seizure were not different from a patient with ADHD alone on their 
performance of a continuous performance task. It had also been observed in various 
studies that children with ADHD and Epilepsy did not respond to stimulants as 
effectively as compared to children with ADHD alone. 
Dunn et al in a study found that majority of children with ADHD only presented 
with combined type, while with Epilepsy and ADHD mostly met the criteria of 
predominantly inattentive type, followed by combined type, followed by 
predominantly hyperactive-impulsive type(74). He also observed that sex of the 
child, seizure type and focus of seizure disorder were not found to predict the 
symptoms of ADHD. Hesdorffer et al in their studies reported the similar finding as 
above(75). Another study evaluated the children with ADHD and Epilepsy after 1 
year of anti-epileptic drugs. It was found that attention problem in children rose 
from 21% to 42% in that period, showing that factors related to Epilepsy or 
treatment had a negative effect on performance(76). 
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II.c.3. Prevalence 
Through various studies and clinical experiences, it is clear that Attention Deficit 
Hyperactivity Disorder is found in a higher percentage of the pediatric population 
with Epilepsy.  
Children with ADHD had almost twice the risk of Epilepsy than children as 
compared to children without ADHD(77). Similar studies done in various part of 
the world supports a strong interrelationship between ADHD and Epilepsy.  
Attention Deficit Hyperactivity Disorder in children and adolescents with Epilepsy 
might be as high as 38%(74). Barkley has estimated the prevalence in a pediatric 
population with Epilepsy to be 20% to 30%(78). 
Mc Dermott et al. reported hyperactivity in 28% of children with Epilepsy as 
compared to 13% of those with heart disease and 5% of controls(79). The analysis 
indicated that children with a seizure disorder were 4.7 times more likely to have a 
behavior problem, while children with cardiac problems were 3 times more likely to 
have behavior problems when compared with controls. The behavior problems 
associated with children with seizures were hyperactive and dependent(79).  
Other study showed that children with unprovoked seizure were 2.5 fold more 
likely to have ADHD(75). It was also noted that age of onset of attention deficit 
hyperactivity disorder was earlier in pediatric age group with Epilepsy as compared 
to without Epilepsy(75). 
 Persistence estimates of attention deficit hyperactivity disorder show that it reduces 
with the age (80).  
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Dunn et al also showed that children with Epilepsy differ from other samples of 
children with ADHD, by an equal male-female ratio(74). This is contrary to as seen 
in general population where the prevalence of ADHD for males is more than 
female(81).  
II.c.4.Effect of medication for ADHD on Epilepsy 
Medication prescribed for the treatment of attention deficit hyperactivity disorder 
may itself affect the threshold of Epilepsy and thus the frequency and severity of 
seizures. Methylphenidate is commonly believed to lower seizure threshold. But in 
a study, Methylphenidate had been shown to have a beneficial effect on EEG and 
the seizure frequency was not changed from baseline. With mild and transient side 
effect with Methylphenidate was found to be is safe and effective in children with 
ADHD and concomitant active seizures or EEG abnormalities(82).  
II.c.5. Effect of Anti-Epileptic Drugs on ADHD symptoms 
Cognitive decline along with behavior problem is well documented with ADHD. 
There are numerous anecdotal reports showing an association of anti-epileptics with 
cognitive decline or behavioral dysfunction, although it has been not been clearly 
demonstrated with controlled studies (83). The main reason for this being the small 
sample size, with wide variations in types and dosages of antiepileptic drugs used, 
types of seizure disorders treated, and treatment duration and outcome. Many such 
studies have conflicting results.  
Few studies demonstrate improvements in cognition or behavior while on 
antiepileptic therapy, possibly as a result of improved seizure control.  
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It is also difficult to determine whether the behavioral changes are due to the 
antiepileptic drugs used or due to seizure control.  
Epileptic patients with coexisting learning disabilities and behavior problems may 
show a sudden increase in alertness and abilities due to improved seizure control. 
Initially, without the social skills or experience to use these new-found abilities in a 
beneficial way, these patients may suddenly appear hyperactive.  
Children and adolescent with Epilepsy on multiple older antiepileptic drugs such as 
Phenobarbital, Phenytoin, and Primidone may benefit from a reduction in the 
number of antiepileptic drugs.(84).  
Poly-therapy anti-epileptic regiments have been found to have a significant 
relationship with behavior problems in few studies while other studies do not 
support it.  
Studies of specific antiepileptic drugs are complex. Patients with different types of 
epilepsies and patients on multiple antiepileptic drugs are often lumped together in 
studies, making it difficult to determine which drug is causing the symptom. It is 
also difficult to determine whether the cognitive impairment is a result of the 
antiepileptic or the underlying neuropsychological disturbance. Moreover, different 
studies compare drugs at different dosage levels which add to the complexity. A 
small sample size and short follow-up weaken the finding of the study. The optimal 
study may be a comparison of seizure-free patients before and after stopping a 
single antiepileptic (85).  
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Phenobarbital has frequently been reported to cause hyperactivity and impairment 
of attention, even in mono-therapy and even in low doses, and behavioral side 
effects are worse with high blood levels(86–92).  
Phenytoin has been reported to cause impairments of various aspects of cognitive 
function, such as memory, motor, and mental speed, but not hyperactivity or 
inattention(93–95). 
Carbamazepine is not thought to cause hyperactivity or inattention and may 
improve alertness and attentiveness in some patients(96–98).  
Whether valproate impairs attention or causes hyperactivity remains a question as 
multiple studies are contradictory(99–104).  
Despite gabapentin‘s beneficial effect as a mood stabilizer, there are numerous case 
reports and small studies indicating that gabapentin causes increased hyperactivity, 
irritability, and aggressive outbursts, particularly in children with preexisting 
behavioral disturbances and developmental disabilities(105–108).  
Lamotrigine, on the other hand, has been demonstrated to cause improvement in 
behavior and attention in numerous small studies, some of which included 
children(108–114).  
There are several reports which suggest that Topiramate has adverse effects on 
attention and cognition, although overall the effects are extremely small(115–118). 
Tiagabine and Oxcarbazepine have not been demonstrated to have any effects on 
behavior or attention(119,120).  
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Studies for Zonisamide and Levetiracetam are non-conclusive(121–125). Risk 
factors for adverse behavioral effects included fast titration rate, history of 
psychiatric disorder, and presence of symptomatic generalized Epilepsy.  
Attention deficit hyperactivity disorder and Epilepsy can individually affect the 
learning, social and behavioral development of children. As such these been 
comorbid in high percentage is expected to have a greater implication on children 
development in all aspects.  Such children are at known risk for academic 
underachievement which can be due to inattention and hyperactivity, and 
appropriate treatment of these problems might improve the scholastic performance. 
II. d. Indian studies 
ADHD in children with Epilepsy is a source of much distress for children and 
caregiver. Though worldwide multiple studies had been conducted to study 
variously related variable, there are a limited number of studies done in Indian 
population or if done, had the limitation of a small sample. 
A study conducted in the pediatric outpatient department observed that the 
prevalence of ADHD was 5.2% in those aged 3-4 years and 29.2% in those aged 
11-12 years. Boys were four times more affected than girls with ADHD. ADHD 
was most common in first-born children and those from a lower socioeconomic 
class. Children with ADHD had a higher rate of pregnancy and delivery-related 
complications, relative to a comparison group. It was also noted that ADHD was 
more associated with delayed development, temper-tantrums, enuresis, tics, broken 
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homes, parental marital discord and psychiatric illness than in the comparison group 
(126). 
Another study of referred children showed that nearly 20.3% children met the 
diagnosis of ADHD with a male-female ratio of 6.3:1 and the mean age was 5.7 
years. Most of the children diagnosed with ADHD belonged to middle and lower 
socio-economic class and were first-born children. Delayed development, 
comorbidity psychiatric illness, and learning disability were more common in 
children with ADHD than normal children.Most children were brought up in 
nuclear families and combined subtype of ADHD was the most common. (127) 
A study of ADHD children presenting to a child guidance clinic in a pediatric 
hospital setup over a one year period reported the prevalence of ADHD to be 
15.5%, with the inattention subtype being predominant with a male to female ratio 
of 6.4:1. It was observed that 27.0% of children had developmental issues. 
Oppositional defiant disorder was most prevalent comorbid psychiatric disorder 
while depression was least. Major religion was Hinduism and most of the families 
were of middle socioeconomic status. They also observed that most of the patients 
were referred by a pediatrician(128). 
 A study conducted in Pediatric neurology out-patient department documented 
23.4% of children with idiopathic Epilepsy to have symptoms of ADHD with a 
mean age of 9.36 years. The inattentive subtype of ADHD was the most common 
type. ADHD was more common among the upper and upper-middle socioeconomic 
status families mostly from a rural background. No consanguinity in parents or 
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relevant family history was present. Generalized seizure with childhood onset, were 
most common among the study sample. Around 30 % of children with Epilepsy and 
ADHD were already on stimulants. Stimulants were not found to be worsening of 
seizures(129). 
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III: AIMS & OBJECTIVES 
III.a. Aim 
To study the prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in 
children and adolescents with Epilepsy and the associated factors 
III.b. Objectives 
1. To study the prevalence and clinical profile of ADHD in children and 
adolescents with Epilepsy. 
2. To study the socio-demographic and illnesses (Epilepsy and ADHD) -related 
factors associated with ADHD in the study population. 
III.c. Hypotheses 
1. The prevalence of ADHD in children and adolescents with Epilepsy is 
different when compared with a child and adolescents without Epilepsy. 
2. Specific predictive factors are associated with ADHD in children and 
adolescents with Epilepsy are when compared with a child and adolescents 
without Epilepsy. 
III.d. Null hypotheses 
1. The prevalence of ADHD in children and adolescents with Epilepsy is not 
different when compared with children and adolescents without Epilepsy. 
2. Specific predictive factors are associated with ADHD in children and 
adolescents with Epilepsy are not different when compared with children and 
adolescents without Epilepsy. 
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IV: METHODOLOGY 
IV. a. Setting 
The study was conducted by the Child and Adolescent Psychiatry Unit of the 
Department of Psychiatry in collaboration with Pediatric Neurology Unit of the 
Department of Neurosciences. The Child and Adolescent Psychiatry Unit is one of 
the four units in the Department of Psychiatry and has both inpatient and outpatient 
services. The Unit has sections for children with various developmental disabilities 
of Intellectual Disability, Autism, Specific Learning Disorders, and ADHD. The 
Emotional and behavioral disorders section has services focused on psychoses, 
mood and other psychiatric disorders among the child and adolescent population. 
The protocol was developed by the Unit for approval by the Institutional Review 
Board.  
The participants were recruited from Paediatric Neurology Clinic, Department of 
Neurosciences, Christian Medical College, Vellore. This is a specialized unit 
offering outpatient, inpatient, emergency and consultation-liaison services to 
patients of the paediatric age group for neurological problems. The diagnosis of 
Epilepsy was made by Paediatric Neurologists based on clinical history and EEG 
findings according to the International League against Epilepsy criteria. The 
participants were recruited for a period of 1-year period, from October 2016 to 
September 2017 if they satisfied the selection criteria. 
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IV.b. Participants 
IV.b.1. Selection criteria 
Inclusion criteria: 
1. Children and adolescents between 4 years to 15 years of age diagnosed to have 
a seizure disorder by the neurologist as per criteria of International League 
against Epilepsy. 
2. Parents should be conversant in English, Tamil, Bengali or Hindi. 
3. Written informed consent obtained from all parents and verbal assent from the 
child or adolescent when feasible. 
Exclusion Criteria 
1. Presence of severe special sensory impairment. 
2. MRI or CT evidence of brain abnormality. 
3. Non-ambulatory, below the moderate level of intellectual functioning as the 
diagnostic accuracy of ADHD decreases.  
IV.b.2. Sample size 
Based on worldwide studies, the prevalence of attention deficit hyperactivity 
disorder in children and adolescents with Epilepsy is around 20% to 38% 
prevalence (74,78,79), and the sample size was calculated as 161 as given in Table 
1.  
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Table 1: Sample-size calculation details 
Single Proportion - Absolute Precision 
Expected  Proportion 0.38 0.38 0.28 0.38 
Precision (%) 5 10 10 7.5 
Desired confidence level  (1- alpha) % 95 95 95 95 
Required sample size 362 91 77 161 
 
 
IV.b.3. Sample selection 
All children and adolescents who had enrolled themselves in the Pediatric 
Neurology Clinic for suspected neurological disorders and available were screened 
and confirmed for Epilepsy. These children and adolescents were assessed for 
ADHD and for other details required for this study if they satisfied the selection 
criteria. Thus a purposive, non-random sampling was used to recruit participants till 
the sample size was achieved. 
IV.b.4. Variables measured in the study 
Dependent variable Measure 
Attention deficit hyperactivity disorder as diagnosed by the ICD-10 criteria. The 
depended variable was dichotomised as ‗case‘ and ‗no-case‘ for the statistical 
analyses. 
54 
 
Independent variables  
Socio-demographic and family variables: Age, gender, socio-economic status, type 
of family, total family member, number of siblings, and birth order. 
Pregnancy-related variables: Term, duration of labor, type of delivery, and fetal 
presentation. 
Perinatal variables: Low birth weight, birth asphyxia, hypoxic-ischemic 
encephalopathy, sepsis, and neonatal jaundice. 
Cognitive and educational variables: Developmental milestones, current academic 
standards, academic performance, and intelligence quotient. 
Epilepsy-related variables: The age of onset, the age at diagnosis, duration of 
disease, seizure semiology, seizure syndrome, EEG findings, MRI-CT imaging 
findings, seizure frequency and duration of last seizure.  
Epilepsy treatment-related variables: Anti-epileptic drugs (AED) prescribed, 
number of AED prescribed, current seizure control, and serum levels of AED. 
Psychiatric and medical comorbidity variables: Comorbid psychiatric disorder, 
treating psychiatric disorder, vitamin D level, medical comorbidity, treating medical 
comorbidity. 
Family history of ADHD, Epilepsy and comorbidity variables: Family history of 
ADHD, degree of family member with ADHD, family history of epilepsy, degree of 
family member with epilepsy, family history of mental illness,degree of family 
member with mental illness,family history of mental retardation, and degree of 
family member with mental retardation. 
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Potential Confounders  
The factor of treatment for ADHD was taken as a potential confounder for the 
prevalence and risk factor study.  
IV.c. Measure and assessment 
Clinical Research Form: Data collection form designed for the study (enclosed). 
This was used to collect information regarding socio-demographic details of the 
children and adolescents, the clinical profile including Epilepsy profile and anti-
epileptics used in last 6 months. 
Clinical diagnoses: 
ICD-10 research criteria - Psychiatric diagnoses of ADHD made by psychiatrists 
based on the tenth edition of the World Health Organization‘s International 
Classification of Diseases (ICD –10) research criteria for Attention deficit 
hyperactivity disorder. 
Criteria Includes: 
The research diagnosis of hyperkinetic disorder requires the presence of abnormal 
levels of inattention and restlessness which are pervasive in various situations and 
are persistent over time.They can be demonstrated by direct observation.They 
should not be caused by other disorders such as autism or affective disorders. Onset 
should be before the age of seven years and duration of the disturbance should be at 
least 6 months. Intelligence quotient should be above 50. 
Epilepsy diagnosis: Epilepsy diagnosis was made by paediatric neurologist based 
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on clinical history and EEG finding according to International League against 
Epilepsy criteria. 
Assessment Scale for Attention Deficit Hyperactivity Disorder: 
Vanderbilt ADHD Diagnostic Parent Rating Scale- The VADPRS is the parents' 
version of the teacher rating scale, the VADTRS (Wolraich et al., 1998, Wolraich et 
al., 1998). It includes all 18 of the DSM-IV criteria for ADHD. In addition, 8 
criteria for oppositional defiant disorder (ODD) and 12 criteria for conduct disorder 
(CD) are included, along with 7 criteria from the Paediatric Behaviour Scale that 
screen for anxiety and depression. The wording has been simplified so that the 
reading level is slightly below third grade. Parents are asked to rate the severity of 
each behavior on a 4-point scale (―never‖ to ―very often‖). The diagnosis is 
considered present if scores of 2 or 3 on a 0–3 scale (indicating that a behavior is 
―often‖ or ―very often‖ present) are checked for the requisite number of criteria 
based on the Attention Deficit Hyperactivity Disorder diagnosis. 
The performance section of the VADPRS is an eight-item scale with four items 
relating to academic performance: (a) overall academic performance, (b) reading, 
(c) mathematics, and (d) written expression. Another four items evaluate 
relationships: (e) peers, (f) siblings, (g) parents, and (h) participation in organized 
activities. The parent rates each of these on a 5-point scale from ―problematic‖ to 
―above average.‖ 
Items (43 for the VADTRS and 45 for the VADPRS) are rated on 4- and 5-point 
scales.Higher scores indicate more severe symptoms, except for the performance 
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section, in which higher scores indicate greater performance in academics and 
classroom behavior. This scale will be administered to the study population and 
both severity and performance domains will be assessed. 
Assessment of functioning in a child: 
Bharat Raj Developmental Screening  
Bharat Raj Development Screening test was developed at all India Institute of 
Speech Pathology and Hearing, Mysore, India(130). This test has a simplified 
version with the age range of 3 months to 15 years. It is found to be quite useful for 
screening functionality and has high validity and reliability. 
Social Economic Status 
Modified Kuppuswamy Scale (revised with income ranges for 2014) 
Modified Kuppuswamy Scale determines the socio-economic status of a family 
taking into account education and occupation of the head of the family along with 
the total per capita income per month. The scale used in the study was a modified 
version of the original 1976 scale-revised for the income ranges in 2014. The scale 
has been modified multiple times before, the last time being in 2012. Based upon 
the total score of the three domains, 5 levels of socio-economic status can be 
obtained which are upper, upper middle, lower middle, upper lower and lower. 
Assessment of Epilepsy and ADHD 
The Epilepsy-related assessments were done by the Paediatric Neurology team and 
the details related to the ADHD and other risk factors were collected by another 
researcher to maintain the independency of the rating for ADHD related variables. 
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IV.d. Data and Statistical analysis 
The data analysis was done to check for missing data, outlier analysis, need for 
transformations and re-categorization of the data to capture the collected details in 
the best possible way to check the hypotheses. The missing data were handled using 
the regression method. The outliers were explored using the Grubbs test (double 
sided with α=0.05) were removed from the analysis. There was no need for 
transformations but the some of the continuous data required re-categorization. 
The participant characteristics were analyzed using descriptive statistics and 
expressed as a percentage or mean [standard deviation (SD)].  
For the hypothesis 1, the prevalence of ADHD among children and adolescents 
were calculated using descriptive statistics and expressed in percentages. The 
prevalence in various subgroups was also expressed in percentages. 
For the hypothesis 2, the predictive factors for ADHD among children and 
adolescents were calculated using univariate and multivariate regression analysis. 
As the dependent variable was the dichotomised ADHD ‗case‘ vs. ADHD ‗no-
case‘, we conducted a series of logistic regression analyses. In the univariate 
regression analyses, one independent variable with constant variable was included 
in the equation for each analysis. In the multivariate analyses, with dichotomised 
ADHD diagnosis as the dependent variable, one independent variable with the 
constant variable and the confounders of treatment for ADHD was in the equation 
for each analysis. 
59 
 
A P value of <0.05 was considered as statistically significant and all tests were 2-
tailed. The analyses were done with statistical software packages of SPSS (version 
15) and MedCalc (version 15.8). 
IV.e. Ethical considerations 
1. Permissions were obtained from the Child and Adolescent Psychiatry Unit 
and Paediatric Neurology Unit before conducting the study. 
2. Methodological and ethical approval from the local Institutional Review 
Board was obtained before conducting the study. 
3. Verbal assent was obtained from the child or adolescents and written when 
possible and informed consent was acquired from the primary caregiver 
always. 
4. Reversible anonymisation and limited availability of the collected data were 
maintained to improve the participant confidentiality. 
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V: RESULTS 
V.a. Participant flow  
A total of 163 children and adolescents with Epilepsy were recruited into the study. 
The flow of participants is described in figure 1, based on the selection criteria. 
 
Figure 1: The flow chart for the participants 
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The outlier analysis using the subscale scores of inattention and hyperactivity did 
not show participants with far outside values (Figure 2). There was no missing data 
for the final analysis. 
Figure: 2. The Box and Whisker plot for the outliers in the subscale of inattention 
and hyperactivity. 
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V.b. Participant Characteristic 
The majority of the participants were children and adolescents were in the range of 
4 to 15 years. Majority of them were boys, from Hindu faith, from West Bengal and 
Tamil Nadu speaking Bangla and Tamil respectively.The participant was primarily 
from upper middle and middle-middle socio-economic status. They were from 
either nuclear or joint family. The participants characteristic is further described in 
table 2. 
 
Table 2: The participant's characteristics. 
 
Demographic variables N (%) N=163 
Chronological age: mean(sd) in years  
Male 
Female 
 
9.93(3.28) 
8.96(3.01) 
Gender         
Male 
Female 
 
107(65.6%) 
56(34.4%) 
Religion 
Hindu 
Muslim 
Christians            
 
126(77.3%) 
15(9.2%) 
22(13.5%) 
Mother Tongue 
Bangla 
Tamil 
Hindi 
English 
Telugu 
Malayalam 
Others 
 
63(38.7%) 
56(34.4%) 
24(14.7%) 
1(0.6%) 
10(6.1%) 
7(4.3%) 
2(1.2%) 
State 
West Bengal 
Tamil Nadu 
Kerala 
Andhra Pradesh 
Others 
 
59(36.2%) 
59(36.2% 
7(4.3%) 
10(6.1%) 
28(17.2%) 
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Table 2: The participant's characteristics.(Continued……) 
 
Demographic variables N (%) N=163 
Socio-economic status 
Upper 
Upper middle 
Middle/Lower middle 
Lower/Upper lower 
 
12(7.4%) 
70(42.9%) 
62(38.0) 
19(11.7) 
Family Structure 
Nuclear 
Extended 
Joint 
 
85(52.1%) 
21(12.9%) 
57(35.0%) 
Parents Marital Status 
Living Together 
Separated 
Divorced 
 
163(100%) 
0(0%) 
0(0%) 
Intelligence Quotient 
Average 
Borderline 
Mild 
Moderate 
 
135(82.8%) 
14(8.6%) 
11(6.7%) 
3(1.8%) 
Academic Performance 
Excellent 
Above average 
Average 
Somewhat of a  problematic 
Problematic 
 
29(17.8%) 
36(22.1%) 
63(38.7%) 
30(18.4%) 
5(3.1%) 
Medical Co-morbidity 
Present 
Absent 
 
7(4.3%) 
156(95.7%) 
Vitamin D Deficiency 
Present 
Absent 
Vitamin D level not done 
 
 
61(37.4%) 
17(10.4%) 
85(52.1%) 
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V.2. Prevalence  
The prevalence of ADHD as per ICD-10 criteria was 11.75% (19/163). The 
prevalence of ADHD was noted in 10% (11/107) of boys and 14% (8/56) of girls 
among the participants. Similarly, ADHD was noted in 15% (15/99) of children 
under 10 years of age and 6% (4/64) of adolescents above 10 years of age. 
V.3. Predictive factors 
The predictive factors as analyzed by the univariate and multivariate logistic 
regression analyses are presented in this subsection. 
 
Table 3: The summary of the Univariate Logistic Regression analysis of the 
demographic and family variables
*
 
 
Variable β(SE) Wald, df Unadjusted 
OR 
P 
value 
Age (years) -0.115(0.079) 2.120,1 0.892 0.145 
 
Gender 
Girls 
Boys 
 
Reference 
-0.375(0.497) 
 
 
0.568,1 
 
 
1.455 
 
 
0.451 
 
SES 
Upper 
Middle & Lower 
 
Reference 
0.354(0.309) 
 
 
1.313,1 
 
 
1.424 
 
 
0.252 
 
Type of Family 
Nuclear 
Extended/Joint 
 
Reference 
0.507(0.269) 
 
 
3.558,1 
 
 
1.661 
 
 
0.059 
 
Total Family Member 0.116(0.064) 3.352,1 1.123 0.067 
 
Number of Siblings 0.542(0.260) 4.331,1 1.719 0.037 
 
Birth Order 
First 
Second,Third,Forth 
 
Reference 
0.378(0.249) 
 
 
2.313,1 
 
 
1.460 
 
 
0.128 
 
*
= constant included in all analyses. 
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It documents that the children and adolescents from extended or joint family, with 
Epilepsy, were at 1.6 times at risk for ADHD when compared with those from a 
nuclear family. Similarly, a total number of a sibling was also associated 1.7 times 
as a risk for developing ADHD when they have Epilepsy. The total number of 
family members showed a statistical trend toward being a risk factor for ADHD. 
The other demographic and family variable of age, gender, SES and birth order 
were not associated with ADHD in this population as noted in Table 3. 
 
Table 4. The summary of the Univariate Logistic Regression analysis of the 
pregnancy-related variables
*
 
 
Variable β(SE) Wald, df Unadjusted 
OR 
P 
value 
Term 
Full term 
Preterm 
Post-term 
 
Reference 
19.213(4.019) 
.000(4.494) 
 
 
0.000,1 
0.000,1 
 
 
2.208 
1.000 
 
 
1.000 
1.000 
 
Duration of Labor 
Normal 
Prolonged 
 
 
Reference 
0.325(0.252) 
 
 
1.661,1 
 
 
1.384 
 
 
0.198 
Type of Delivery 
Normal 
Instrumental 
Operation 
 
Reference 
-0.265(0.490) 
-19.340(2.842) 
 
 
0.292,1 
0.000,1 
 
 
0.767 
0.000 
 
 
0.589 
0.999 
 
Abnormal Fetal 
Presentation 
No 
Yes 
 
 
 
Reference 
19.184(4.019) 
 
 
 
0.000,1 
 
 
 
2.146 
 
 
 
1.000 
 
*
= constant included in all analyses. 
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As noted in Table 4, none of the factors namely the Term at birth, duration of labor, 
type of delivery, the fetal presentation were associated with ADHD in children with 
Epilepsy. 
 
 
 
Table 5. The summary of the Univariate Logistic Regression analysis of the 
perinatal variables
*
 
 
Variable β(SE) Wald, df Unadjusted 
OR 
P value 
Low Birth Weight 
No 
Yes 
 
 
Reference 
0.492(1.071) 
 
 
0.212,1 
 
 
1.636 
 
 
0.646 
Birth Asphyxia 
No 
Yes 
 
Reference 
-0.693(0.831) 
 
 
0.695,1 
 
 
0.500 
 
 
0.404 
 
HIE 
No 
Yes 
 
Reference 
19.184(4.019) 
 
 
0.000,1 
 
 
2.146 
 
 
1.000 
 
Sepsis 
No 
Yes 
 
Reference 
-19.184(0.019) 
 
 
0.000,1 
 
 
0.000 
 
 
1.000 
 
Neonatal Jaundice 
No 
Yes 
 
Reference 
0.834(0.842) 
 
 
0.981,1 
 
 
2.303 
 
 
0.322 
 
 
*
= constant included in all analyses. 
 
As noted in Table 5, none of the factors namely the Low birth weight, birth 
asphyxia, presence of evidence of hypoxic-ischemic encephalopathy, neonatal 
sepsis, and neonatal jaundice were associated with ADHD in children with 
Epilepsy. 
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Table 6: The summary of the Univariate Logistic Regression analysis of cognitive 
and educational variables
*
 
 
Variable β(SE) Wald, df Unadjust
ed OR 
P value 
Developmental 
Milestones 
On time 
Delayed 
 
 
Reference 
-0.503(0.612) 
 
 
 
0.675,1 
 
 
 
0.605 
 
 
 
0.411 
 
Current Academic 
Standard 
 
-0.120(0.075) 
 
2.573,1 
 
0.887 
 
0.109 
 
Academic Performance 
Excellent 
Above Average 
Average 
Somewhat Problematic 
Problematic 
 
Reference 
-19.817(7.464) 
-2.169(1.509) 
-0.693(1.188) 
0.693(1.183) 
 
 
0.000,1 
2.065,1 
0.341,1 
0.343,1 
 
 
0.000 
0.114 
0.500 
2.000 
 
 
0.998 
0.151 
0.559 
0.558 
 
Intelligence Quotient 
Average 
Borderline 
Mild 
Moderate 
 
Reference 
1.506(0.670) 
1.442(0.747) 
1.729(1.265) 
 
 
5.052,1 
3.729,1 
1.870,1 
 
 
4.509 
4.227 
5.636 
 
 
0.025 
0.053 
0.171 
 
 
*
= constant included in all analyses. 
 
Among the cognitive and education related variable of the participants, only the 
intelligence quotient was associated with the ADHD.Having the borderline 
intelligence was associated 4.5 times and having a mild intellectual disability was 
associated with 4.2 times of having ADHD. The other factors of delayed 
developmental milestones, a current academic level achieved and academic 
performance abilities were not associated with ADHD as noted in Table 6. 
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Table 7: The summary of the Univariate Logistic Regression analysis of Epilepsy-
related variables
*
 
 
Variable β(SE) Wald, df Unadjusted 
OR 
P value 
Age of Onset -0.010(0.006) 2.193,1 0.990 0.139 
Age of Diagnosis -0.010(0.006) 2.580,1 0.990 0.108 
Duration of Disease 0.001(0.006) 0.014,1 1.001 0.907 
Seizure Semiology 0.241(0.487) 0.246,1 1.273 0.620 
Seizure Syndrome 0.038(0.058) 0.424,1 1.039 0.515 
EEG 
Normal 
Abnormal 
 
Reference 
-0.300(0.489) 
 
 
0.377,1 
 
 
0.741 
 
 
0.539 
 
MRI/CT 
MRI-N 
CT-N 
MRI Subtle 
 
Reference 
-0.628(1.067) 
0.912(1.183) 
 
 
0.347,1 
0.595,1 
 
 
0.534 
2.490 
 
 
0.556 
0.441 
 
Seizure Frequency 
1 Seizure/several years 
1-11 Seizures/year 
1-3 Seizures/month 
1-6 Seizures/week 
Daily Seizure  
 
Reference 
2.222(1.296) 
1.934(1.263) 
2.627(0.772) 
1.662(0.703) 
 
 
2.940,1 
2.344,1 
11.592,1 
5.589,1 
 
 
9.222 
6.917 
13.833 
5.270 
 
 
0.086 
0.126 
0.001 
0.018 
 
Duration since last 
Seizure 
 
-0.063(0.025) 
 
6.246,1 
 
0.939 
 
0.012 
 
 
*
= constant included in all analyses. 
 
Among Epilepsy-related variables, the seizure frequency and duration since last 
seizure was significantly associated with ADHD. Having a seizure frequency of 1-6 
seizure per week was 13.8 times at risk of being associated ADHD, while daily 
seizures were associated with 5.2 times higher risk of being associated with ADHD. 
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All the above mention risks were when compared with 1 seizure in several years.It 
showed that longer the duration since the last seizure more the protective factor 
associated with ADHD.The age of onset of Epilepsy, the age at diagnosis of 
Epilepsy, duration of disease, seizure semiology, seizure syndrome, EEG 
abnormality, and imaging abnormalities were not associated with ADHD in 
children with Epilepsy. 
 
Table 8: The summary of the Univariate Logistic Regression analysis of Epilepsy 
treatment-related variables
*
 
 
Variable β(SE) Wald, df Unadjusted 
OR 
P 
value 
AED 19.192(2.842) 0.000,1 2.162 0.999 
 
Number of AED 
No AED 
Single/Multiple AED 
 
Reference 
0.488(0.299) 
 
 
2.665,1 
 
 
1.629 
 
 
0.103 
 
Current Seizure Control 
Yes 
No 
 
Reference 
1.951(0.553) 
 
 
12.456,1 
 
 
7.034 
 
 
0.000 
 
Compliance of AED 
Yes 
No 
 
Reference 
-19.184(4.019) 
 
 
0.000,1 
 
 
0.000 
 
 
1.000 
 
Serum AED Level 
Adequate 
Inadequate/Not Done 
 
Reference 
0.501(0.591) 
 
 
0.718,1 
 
 
1.650 
 
 
0.397 
 
 
*
= constant included in all analyses. 
 
Among the factors related to the treatment of Epilepsy, only no current seizure 
control was statically significantly was associated with ADHD. Not having current 
seizure control when compared with achieving current seizure control was 7 times 
at risk of being related to ADHD. The factors of a dose of AED, number of AED, 
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compliance of AED and Serum AED level were not associated with ADHD among 
children and adolescents with Epilepsy, as noted in table 8. 
 
Table 9: The summary of the Univariate Logistic Regression analysis of psychiatric 
and medical comorbidity variables
*
 
 
Variable β(SE) Wald, df Unadjusted 
OR 
P value 
Comorbid Psychiatric 
Disorder 
No 
Yes 
 
 
Reference 
-19.184(4.019) 
 
 
 
0.000,1 
 
 
 
0.000 
 
 
 
1.000 
 
Treating Psychiatric 
Disorder 
No 
Yes 
 
 
Reference 
19.184(4.019) 
 
 
 
0.000,1 
 
 
 
2.146 
 
 
 
1.000 
 
Vitamin D Level 0.067(0.033) 4.225,1 1.069 0.040 
 
Medical Comorbidity 
None 
Present 
 
Reference 
0.245(1.109) 
 
 
0.049,1 
 
 
1.278 
 
 
0.825 
 
Treating Medical 
Comorbidity 
No 
Yes 
 
 
Reference 
-0.237(0.585) 
 
 
 
0.164,1 
 
 
 
0.789 
 
 
 
0.686 
 
 
*
= constant included in all analyses. 
 
Table 9 documents that only the factor of low vitamin D level was statically 
significantly associated with ADHD when compared with normal levels of vitamin 
D level. The children and adolescents with low vitamin D level were at 1 fold at 
risk of being associated with ADHD among this population. The comorbid 
psychiatric disorder, medical comorbidity, and treatment of other comorbidity were 
not associated with ADHD in Epilepsy.  
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Table 10: The summary of the Univariate Logistic Regression analysis of the family 
history of ADHD, Epilepsy and comorbidity variables
*
 
 
Variable β(SE) Wald, df Unadjusted 
OR 
P 
value 
Family History of ADHD 
 No 
 Yes 
 
 
 
Reference 
-0.057(1.090) 
 
 
 
0.003,1 
 
 
 
0.944 
 
 
 
0.958 
Degree of Family 
Member with ADHD 
1
st
 
2
nd
,3rd 
 
 
Reference 
-0.045(0.567) 
 
 
 
0.006,1 
 
 
 
0.956 
 
 
 
0.937 
 
Family History of 
Epilepsy 
No 
Yes 
 
 
 
Reference 
0.243(0.529) 
 
 
 
0.212,1 
 
 
 
1.275 
 
 
 
0.645 
Degree of Family 
Member with Epilepsy 
1
st
 
2
nd
,3rd 
 
 
Reference 
-0.189(0.238) 
 
 
 
0.636,1 
 
 
 
0.827 
 
 
 
0.425 
 
Family History of Mental 
Illness 
  No 
  Yes 
 
 
 
Reference 
-19.385(7.735) 
 
 
 
0.000,1 
 
 
 
0.000 
 
 
 
0.998 
Degree of Family 
Member with Mental 
Illness 
1
st
 
2
nd
,3rd 
 
 
 
Reference 
16.357(4.421) 
 
 
 
 
0.000,1 
 
 
 
 
1.270 
 
 
 
 
0.997 
 
Family History of Mental 
Retardation 
 No 
Yes 
 
 
 
Reference 
1.814(0.700) 
 
 
 
6.706,1 
 
 
 
 
6.133 
 
 
 
0.010 
Degree of Family 
Member with Mental 
Retardation 
 3
rd
 and above 
2
nd
 
 
 
 
Reference 
1.881(0.808) 
 
 
 
 
5.421,1 
 
 
 
 
6.562 
 
 
 
 
0.020 
 
 
*
= constant included in all analyses. 
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Table 10 summarizes the family history of ADHD, Epilepsy and other 
comorbidities. The factors of family history of intellectual disability and the degree 
of relationship of the family member with intellectual disability were statically 
significantly associated with ADHD. The presence of family history of intellectual 
disability, when compared with no such history, was 6 times more at risk of being 
associated with ADHD. Similarly, the closer the relationship between the family 
members with an intellectual disability, 6.5 times is the risk of ADHD being noted 
in this population with Epilepsy.The family history of ADHD, the degree of relation 
with the family member of ADHD, family history of Epilepsy, the degree of 
relationship with the family member with Epilepsy, family history of mental illness, 
the degree of relationship with the member with mental illness were not associated 
with ADHD. 
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Table 11: The summary of the Multivariate Logistic Regression analysis of the 
demographic and family variables
*,† 
 
Variable β(SE) Wald, df Adjusted 
OR 
95% CI of 
OR 
P 
value 
Lower Upper 
Age (years) -0.073(0.084) 0.751,1 0.930 0.789 1.096 0.386 
Gender 
Girls 
Boys 
 
Reference 
0.182(0.546) 
 
 
0.112,1 
 
 
1.200 
 
 
0.412 
 
 
3.498 
 
 
0.738 
 
 
SES 
Upper 
Middle & Lower 
 
Reference 
0.378(0.335) 
 
 
1.273,1 
 
 
1.460 
 
 
0.757 
 
 
2.816 
 
 
0.259 
Type of Family   
Nuclear 
Extended/Joint 
 
Reference 
0.404(0.285) 
 
 
2.001,1 
 
 
1.497 
 
 
0.856 
 
 
2.620 
 
 
0.157 
 
Total Family Member  
0.106(0.067) 
 
2.543,1 
 
1.112 
 
0.976 
 
1.268 
 
0.111 
 
Number of Siblings 0.421(0.281) 2.245,1 1.523 0.878 2.642 0.134 
Birth Order 
First 
Second,Third,Forth 
 
Reference 
0.218(0.290) 
 
 
0.569,1 
 
 
1.244 
 
 
0.705 
 
 
2.195 
 
 
0.450 
 
Type of Family   
Nuclear 
Extended/Joint 
 
Reference 
0.404(0.285) 
 
 
2.001,1 
 
 
1.497 
 
 
0.856 
 
 
2.620 
 
 
0.157 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
 
 
 
Table 11 represents the relationship between demographic aswell family variables 
and ADHD in Epilepsy when the confounding variable of treatment for ADHD was 
controlled. The factors of the type of family and number of siblings that were 
significant in the univariate analysis lost their significance in the multivariate 
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regression analysis. The other factors related to demography and family did not gain 
significance. 
 
Table 12: The summary of the Multivariate Logistic Regression analysis of the 
pregnancy-related variables
*,† 
 
Variable β(SE) Wald, 
df 
Adjuste
d OR 
95% CI of 
OR 
P 
value 
Lower Upper 
Term 
Full term 
Preterm 
Post-term 
 
Reference 
-19.041(2.010) 
-19.041(4.019) 
 
 
0.000,1 
0.000,1 
 
 
0.000 
0.000 
 
 
0.000 
0.000 
 
 
0.000 
0.000 
 
 
0.999 
1.000 
Duration of Labor 
Normal 
Prolonged 
 
 
Reference 
0.323(0.271) 
 
 
1.419,1 
 
 
1.381 
 
 
0.812 
 
 
2.350 
 
 
0.234 
Type of Delivery 
Normal 
Instrumental 
Operation 
 
Reference 
-18.852(2.842) 
0.370(0.528) 
 
 
0.000,1 
0.491,1 
 
 
0.000 
1.448 
 
 
0.000 
0.514 
 
 
0. 
4.079 
 
 
0.999 
0.483 
 
Abnormal 
Presentation 
No 
Yes 
 
 
Reference 
-19.013(4.019) 
 
 
 
0.000,1 
 
 
 
0.000 
 
 
 
0.000 
 
 
 
0.0 
 
 
 
1.000 
 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
 
 
Table 12 represents the relationship between pregnancy-related variables and 
ADHD in Epilepsy when the confounding variable of treatment for ADHD was 
controlled. The factors of the term at pregnancy, duration of labor, type of delivery 
and abnormal fetal presentation were not significant in the multivariate analysis as 
was with univariate analysis. 
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Table 13: The summary of the Multivariate Logistic Regression analysis of the peri-
natal variables
*,† 
 
Variable β(SE) Wald, 
df 
Adjusted 
OR 
95% CI of 
OR 
P 
value 
Lower Upper 
Low Birth Weight 
No 
Yes 
 
 
Reference 
-0.310(1.076) 
 
 
 
0.083,1 
 
 
 
0.733 
 
 
 
0.089 
 
 
 
6.041 
 
 
 
0.773 
 
Birth Asphyxia 
No 
Yes 
 
Reference 
0.887(0.839) 
 
 
1.119,1 
 
 
2.429 
 
 
0.469 
 
 
12.573 
 
 
0.290 
 
HIE 
No 
Yes 
 
Reference 
-19.013(4.019) 
 
 
0.000,1 
 
 
0.000 
 
 
0.000 
 
 
0. 
 
 
1.000 
 
Sepsis 
No 
Yes 
 
Reference 
-19.013(4.019) 
 
 
0.000,1 
 
 
0.000 
 
 
0.000 
 
 
0. 
 
 
1.000 
 
Neonatal Jaundice 
No 
Yes 
 
 
Reference 
-1.028(0.849) 
 
 
 
1.465,1 
 
 
 
0.358 
 
 
 
0.068 
 
 
 
1.890 
 
 
 
0.226 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
 
 
 
Table 13 represents the relationship between perinatal variables and ADHD in 
Epilepsy when the confounding variable of treatment for ADHD was controlled. 
Thus the factors of low birth weight, birth asphyxia, hypoxic-ischemic 
encephalopathy, neonatal sepsis and neonatal jaundice like in the univariate analysis 
were not associated with ADHD in multivariate analysis as well. 
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Table 14: The summary of the Multivariate Logistic Regression analysis of 
cognitive and educational variables
*,† 
 
Variable β(SE) Wald, 
df 
Adjust
ed OR 
95% CI of 
OR 
P 
value 
Lower Upper 
Developmental 
Milestones 
On time 
Delayed 
 
 
Reference 
0.358(0.684) 
 
 
 
0.274,1 
 
 
 
1.431 
 
 
 
0.374 
 
 
 
5.471 
 
 
 
0.601 
 
Current Academic 
Standard 
-0.085(0.080) 1.139,1 0.918 0.785 1.074 0.286 
Academic Performance 
Excellent 
Above Average 
Average 
Somewhat Problematic 
Problematic 
 
 
Reference 
17.648(7.464) 
18.969(7.464) 
20.287(7.464) 
19.817(7.464) 
 
 
 
0.000,1 
0.000,1 
0.000,1 
0.000,1 
 
 
 
4.616 
1.731 
6.462 
4.039 
 
 
 
0.000 
0.000 
0.000 
0.000 
 
 
 
0. 
0. 
0. 
0. 
 
 
 
0.998 
0.998 
0.998 
0.998 
 
Intelligence Quotient 
Average 
Borderline 
Mild 
Moderate 
 
Reference 
-1.825(1.268) 
-0.511(1.390) 
-0.693(1.458) 
 
 
2.070,1 
0.135,1 
0.226,1 
 
 
0.161 
0.600 
0.500 
 
 
0.013 
0.039 
0.029 
 
 
1.936 
9.156 
8.706 
 
 
0.150 
0.713 
0.634 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
 
 
Table 14 represents the relationship between cognitive and educational variables 
and ADHD in Epilepsy when the confounding variable of treatment for ADHD was 
controlled. The factors of intelligence quotient type that were significant in the 
univariate analysis lost their significance in the multivariate regression analysis. 
The other factors of delay in developmental milestones, a current academic level 
achieved and current academic performance ability did not gain significance. 
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Table 15: The summary of the Multivariate Logistic Regression analysis of 
Epilepsy-related variables
*,† 
 
Variable β(SE) Wald, 
df 
Adjus
ted 
OR 
95% CI of 
OR 
P value 
Lower Upper 
Age of Onset -0.006(0.007) 0.814,1 0.994 0.981 1.007 0.367 
 
Age of Diagnosis -0.007(0.007) 1.028,1 0.993 0.981 1.006 0.311 
Duration of Disease 0.001(0.007) 0.010,1 1.001 0.988 1.014 0.918 
Seizure Semiology 0.337(0.548) 0.378,1 1.401 0.479 4.098 0.538 
Seizure Syndrome 0.051(0.062) 0.675,1 1.052 0.932 1.188 0.411 
EEG 
Normal 
Abnormal 
 
Reference 
-0.195(0.527) 
 
 
0.137,1 
 
 
0.823 
 
 
0.293 
 
 
2.313 
 
 
0.711 
 
MRI/CT 
MRI-N 
CT-N 
MRI Subtle 
 
Reference 
-1.107(1.189) 
-1.540(1.551) 
 
 
0.867,1 
0.987,1 
 
 
0.331 
0.214 
 
 
0.032 
0.010 
 
 
3.397 
4.477 
 
 
0.352 
0.321 
 
Seizure Frequency 
1Seizure/severalyears 
1-11 Seizures/year 
1-3 Seizures/month 
1-6 Seizures/week 
Daily Seizure 
 
 
Reference 
2.288(1.296) 
1.934(1.263) 
2.627(0.772) 
1.192(0.754) 
 
 
2.940,1 
2.344,1 
11.592,1 
2.496,1 
 
 
9.222 
6.917 
13.83 
3.294 
 
 
0.728 
0.582 
3.049 
0.751 
 
 
116.87 
82.231 
62.766 
14.450 
 
 
0.086 
0.126 
0.001 
0.114 
Duration since last 
Seizure 
 
-0.059(0.026) 
 
5.088,1 
 
0.943 
 
0.896 
 
0.992 
 
0.024 
 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
 
 
 
Table 15 represents the relationship between Epilepsy-related variables and ADHD 
in Epilepsy when the confounding variable of treatment for ADHD was controlled. 
The two variables of seizure frequency and duration since last seizure were 
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statically and significantly were related to the ADHD in Epilepsy as in the 
univariate analysis. The frequency of seizures at 1- 6 times a week was 13.8 times 
was related with ADHD in Epilepsy. The frequency of 1-11 times a year showed 
only statistical trends toward association with Epilepsy. The other Epilepsy was not 
associated with ADHD in Epilepsy. Also, the duration since the last seizure showed 
that longer the duration less is the risk of being associated with ADHD with 
Epilepsy. 
 
 
Table 16: The summary of the Multivariate Logistic Regression analysis of 
Epilepsy treatment-related variables
*,† 
 
Variable β(SE) Wald, df Adjusted 
OR 
95% CI of 
OR 
P 
value 
Lower Upper 
AED 19.020(2.842) 0.000,1 1.820 0.000 0. 0.999 
Number of AED 
No AED 
Single/Multiple AED 
 
Reference 
0.528(0.318) 
 
 
2.573,1 
 
 
1.696 
 
 
0.909 
 
 
3.163 
 
 
0.097 
 
Current Seizure 
Control 
Yes 
No 
 
 
Reference 
2.020(0.606) 
 
 
 
11.103,1 
 
 
 
7.537 
 
 
 
2.297 
 
 
 
24.725 
 
 
 
0.001 
 
Compliance of AED 
Yes 
No 
 
Reference 
19.013(4.019) 
 
 
0.000,1 
 
 
1.808 
 
 
0.000 
 
 
0. 
 
 
1.000 
 
Drug Serum Level 
Adequate 
Inadequate/Not Done 
 
Reference 
0.645(0.666) 
 
 
0.940,1 
 
 
1.907 
 
 
0.517 
 
 
7.028 
 
 
0.332 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
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Table 16 represents the relationship between Epilepsy treatment-related variables 
and ADHD in Epilepsy when the confounding variable of treatment for ADHD was 
controlled. The only factor statically significantly associated was the current control 
of seizures. Lack of current seizure control was 7.5 times more at risk of being 
associated with ADHD in Epilepsy. The other Epilepsy treatment-related factors 
were not associated with ADHD in Epilepsy.  
 
Table 17: The summary of the Multivariate Logistic Regression analysis of 
psychiatric and medical comorbidity variables
*,†
 
 
Variable β(SE) Wald, 
df 
Adjust
ed OR 
95% CI of 
OR 
P 
value 
Lower Upper 
Comorbid Psychiatric 
Disorder 
No 
Yes 
 
 
Reference 
-19.013(4.019) 
 
 
 
0.000,1 
 
 
 
0.000 
 
 
 
0.000 
 
 
 
0. 
 
 
 
1.000 
 
Treating Psychiatric 
Disorder 
No 
Yes 
 
 
Reference 
19.013(4.019) 
 
 
 
0.000,1 
 
 
 
1.808 
 
 
 
0.000 
 
 
 
0. 
 
 
 
1.000 
 
Vitamin D Level 0.072(0.039) 3.420,1 1.075 0.996 1.161 0.064 
Medical Comorbidity 
No 
Yes 
 
 
Reference 
0.427(1.114) 
 
 
 
0.147,1 
 
 
 
1.533 
 
 
 
0.173 
 
 
 
13.606 
 
 
 
0.701 
 
Treating Medical 
Comorbidity 
No 
Yes 
 
 
Reference 
-0.335(0.586) 
 
 
 
0.326,1 
 
 
 
0.715 
 
 
 
0.227 
 
 
 
2.258 
 
 
 
0.568 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
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Table 17 represents the relationship between psychiatric and medical comorbidity 
variables and ADHD in Epilepsy when the confounding variable of treatment for 
ADHD was controlled. The only factor that demonstrated a statically significant 
trend towards being a risk for ADHD in Epilepsy was low serum vitamin D 
level.The risk of ADHD in Epilepsy was 1 fold more with low serum vitamin d 
level in comparison to normal vitamin serum level.The other psychiatric and 
medical comorbidity were not associated with ADHD. 
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Table 18: The summary of the Multivariate Logistic Regression analysis of the 
family history of ADHD, Epilepsy and comorbidity variables
*,† 
 
Variable β(SE) Wald, df Adjuste
d OR 
95% CI of 
OR 
P 
value 
Lower Upper 
Family History of 
ADHD 
No 
Yes 
 
 
Reference 
-0.125(1.095) 
 
 
 
0.013,1 
 
 
 
0.882 
 
 
 
0.103 
 
 
 
7.546 
 
 
 
0.909 
 
Family History of 
Epilepsy 
No 
Yes 
 
 
Reference 
0.082(0.608) 
 
 
 
0.018,1 
 
 
 
1.086 
 
 
 
0.330 
 
 
 
3.572 
 
 
 
0.892 
 
Family History of 
Mental Illness 
No 
Yes 
 
 
Reference 
19.213(7.735) 
 
 
 
0.000,1 
 
 
 
2.209 
 
 
 
0.000 
 
 
 
0. 
 
 
 
0.998 
 
Family History of 
Mental 
Retardation 
 No 
Yes 
 
 
 
Reference 
2.037(0.712) 
 
 
 
 
8.179,1 
 
 
 
 
7.667 
 
 
 
 
1.898 
 
 
 
 
30.963 
 
 
 
 
0.004 
 
Degree of Family 
Member with 
Mental 
Retardation 
 3
rd
 and above. 
2nd 
 
 
 
 
Reference 
2.089(0.817) 
 
 
 
 
 
6.539,1 
 
 
 
 
 
8.077 
 
 
 
 
 
1.629 
 
 
 
 
 
40.053 
 
 
 
 
 
 
0.011 
 
 
*
= constant included in all analyses.
 
†
= ADHD treatment controlled for its confounding effect.
 
 
 
 
 
Table 18 represents the relationship between family history of ADHD, Epilepsy and 
comorbidity variables and ADHD in Epilepsy when the confounding variable of 
treatment for ADHD was controlled. As with univariate, the multivariate analysis 
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also demonstrated that family history of intellectual disability and the degree of 
familial relationship with the member of intellectual disability was 7.6 times and 8 
times at risk of being associated with ADHD. The family history of other illness 
was not associated with ADHD. 
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VI: DISCUSSION 
 
This section briefs the findings and discusses them in the light of the existing 
research findings in these interesting overlapping disorders of ADHD and Epilepsy, 
lists out the strengths and caveats of the study, its utility as well as future directions. 
VI. a. Summary of findings in the study. 
The overall prevalence of ADHD in participants is 11.7% and was more among 
girls and children.Children and adolescents with Epilepsy, from extended or joint 
family, the total number of a sibling, lower intelligence quotient, seizure frequency 
and duration since last seizure, no current seizure control was significantly 
associated with ADHD. Also, the presence of family history of intellectual 
disability and the closer relationship to the person intellectual disability were 
statically significantly associated with ADHD. 
None of the factors namely the term at birth, duration of labor, type of delivery, the 
fetal presentation were associated with ADHD in children with Epilepsy. Similarly, 
none of the factors namely the Low birth weight, birth asphyxia, presence of 
evidence of hypoxic-ischemic encephalopathy, neonatal sepsis, and neonatal 
jaundice, delayed developmental milestones, current academic level achieved and 
academic performance abilities were not associated with ADHD. 
Among the factors, related Epilepsy and its treatment, dose of AED, number of 
AED, compliance of AED and Serum AED level were not associated with ADHD 
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among children and adolescents with Epilepsy. Family histories of ADHD or 
psychiatric and medical comorbidities were also not related to ADHD among 
children and adolescents with Epilepsy. 
VI. b. Comparisons of findings in the study. 
Prevalence: 
The worldwide prevalence of ADHD in children ranges from 20% to 38% in 
various studies (11–13), while in India the prevalence of ADHD in Epileptic 
children was around 23.4%(129). The overall prevalence of ADHD in participants 
is 11.7% in our study. It supports that finding that Epilepsy is associated with 
ADHD though overall prevalence in this study was low which could be due to 
different methodology, different study population, and setting.  
Demographic and Family Variable: 
The study found that in the age group below 10 years the prevalence of ADHD is 15 
%, while above 10 years of age the prevalence was 6 %. This supports various 
studies which show that the prevalence of ADHD decreases with increasing 
age(60). 
Within gender, 10.3% of male and 14.3% of the female were diagnosed with 
ADHD, which supports that the gender difference in term of the prevalence of 
ADHD in children and adolescents was much less as compared to children without 
Epilepsy.(11, 68, 82) 
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The socioeconomic status was not associated with ADHD in this study but another 
similar study conducted in Indian population showed association with upper and 
upper-middle socioeconomic status(129). 
Pregnancy-related variables: 
None of the factors namely the Term at birth, duration of labor, type of delivery, the 
fetal presentation were associated with ADHD in children with Epilepsy. No 
previous study conducted, show any association and report similar finding as this 
study.  
Perinatal variables 
Low birth weight, birth asphyxia, the presence of evidence of hypoxic-ischemic 
encephalopathy, neonatal sepsis, and neonatal jaundice were found associated with 
ADHD in children with Epilepsy in this study. Previous studies give ambivalent 
results and most of these studies were conducted on small sample size. 
Cognitive and educational variables 
This study documented that the intelligence quotient was associated with the 
ADHD. This was contrary to another large study where intelligence quotient had no 
such association.(131). Our study showed that having the borderline intelligence 
was associated 4.5 times and having a mild intellectual disability was associated 
with 4.2 times of having ADHD.  
Epilepsy-related variables 
The seizure frequency significantly associated with ADHD but previous studies do 
not support this finding(132). 
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Previous studies show that the seizure semiology, seizure syndrome, EEG 
abnormality, and imaging abnormalities were not associated with ADHD in 
children with Epilepsy in this study. This study supports the finding from the 
previous study(132). The age of the onset and duration of Epilepsy was not found to 
be associated with ADHD in this study but a similar study done in China by Kwong 
et al shows association in with both variables(132). 
Epilepsy treatment-related variables 
No current control of seizure was statically significantly associated with ADHD in 
the present study which is contrary to the findings in the previous large studies 
where no such association was found(132). Not having current seizure control when 
compared with achieving current seizure control was 7 times at risk of being related 
to ADHD in the present study. On the other hand, previous studies support an 
association with a number of AED but the present study does not support this 
association with ADHD among children and adolescents with Epilepsy(132). 
Psychiatric and medical comorbidity variables 
The comorbid psychiatric disorder had shown association in previous studies and 
same is supported by this study.Presence of medical comorbidity has been shown to 
have an association with ADHD in children with Epilepsy(132), but this is not 
supported by this study. 
Family history of ADHD, Epilepsy and comorbidity variables 
The family history of ADHD or mental illness was not associated with ADHD. This 
was supported by similar finding in a recent Indian study(129), but other study 
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conducted in Kwong et al showed a positive association with first degree relative 
with psychiatric illness(132). 
VI. c. Strengths of the study: 
1. The study design included multiple variables associated with ADHD in 
participants. 
2. The diagnosis of ADHD made by a psychiatrist was supported by ICD-10 
diagnosis and Vanderbilt scale for ADHD. 
3. The sample size required was achieved and thus the power of the findings 
was not compromised. 
4. The diagnosis of Epilepsy was made by Pediatric neurologist based on ILAE 
criteria, thus chances of misdiagnosis of Epilepsy was minimised. 
5. The study sample population is similar in terms of the socio-demographic 
profile of earlier Indian studies and hence the results can be compared to 
existing literature. 
6. Since the participants represented from different parts of the country the 
findings can be generalized clinically. 
VI. d. Limitations of the study: 
This study was conducted in a tertiary care set up, hence generalization of the study 
results to primary and secondary care settings is not possible. 
The sampling was not randomized and hence sampling errors are possible. 
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In view of chronicity of symptoms and caregivers not always accompanying the 
participants, the reliability of the caregiver's information was sometimes 
questionable. 
There is are limited similar studies done in past in India thus adequate data to 
compare the finding are not available. 
VI.e. Utility of the study: 
This study has documented the prevalence of ADHD in children and adolescents 
with ADHD as well as identifying the risk and protective factor associated with this 
condition in this population. Thus this study paves the way to the development of a 
score card for predicting the risk of developing ADHD among children and 
adolescents with Epilepsy. 
VI. f. Future directions: 
Larger studies with multi-centric methodology are required to further confirm the 
established prevalence and predictive factors are required which should have 
representation from multiple socio-cultural backgrounds. Studies should include 
samples from primary and secondary care settings to improve the generalizability of 
the findings. 
VI.g. Conclusion 
The two hypotheses, on the prevalence and risk factors, were substantiated in this 
study. The study has proved the proposed hypothesis that the prevalence of ADHD 
in the children and adolescents with Epilepsy is different than the prevalence of 
ADHD in children and adolescents in general population. The risk factors 
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associated with ADHD in Epileptic is also different from the risk factor associated 
with ADHD in general population as compared in the literature survey. 
90 
 
VII: SUMMARY 
1. The two hypotheses on the prevalence and risk factors associated with 
ADHD among children and adolescents were studied and established as 
proposed. 
2. The prevalence of ADHD in children with Epilepsy is about 12%, and 
thus much higher than in general population. 
3. The prevalence of ADHD among children was more than in adolescent 
with Epilepsy as expected. 
4. The prevalence of ADHD was more among girls than among boys, which 
the reverse of that noted in the general population.  
5. The factors being from an extended or joint family, a higher number of a 
sibling, lower intelligence quotient, high seizure frequency and short 
duration since last seizure, no current seizure control, the presence of a 
family member with an intellectual disability and the closeness of the 
family relationship of that person were statically associated with ADHD. 
6. The a priori sample size was collected and the power of the study was 
maintained. 
7. The sampling and assessment bias was minimized with appropriate 
sampling techniques and diagnosis of Epilepsy and ADHD by two 
independent teams respectively. 
8. Generalizability remains a caveat as the study was conducted in a 
tertiary-care setting. 
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9. This study opens the way for developing risk scores for developing 
ADHD among those children and adolescent with Epilepsy. 
10. Multi-centric studies including participants from primary and secondary 
care settings are suggested. 
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APPENDIX-1 
 INFORMATION SHEET-English 
 
Christian Medical College Vellore  
        Department of Psychiatry & Department of Neurology 
 
Title: A study ofprevalence and factors associated with attention deficit 
hyperactivity disorder in Children and Adolescents with Epilepsy. 
 
 
 
 
You and your ward are being requested to take part in a study which aims to see the 
prevalence of attention deficit hyperactivity disorder in children and adolescents with 
epilepsy, and their clinical profile, along with their social demographic characteristics. It 
also aims to study effect of factors like duration of epilepsy, age of onset of epilepsy, anti-
epileptic used, subtype of epilepsy and control of seizure, on attention deficit hyperactivity 
disorder distribution. It is known that attention deficit hyperactivity disorder and epilepsy 
can individually effect the learning, social and behavioral development of children. These 
two being together is expected to have greater implication on children development in all 
aspects.  Such children are at known risk for academic underachievement which can be due 
to inattention and hyperactivity, and appropriate treatment of these problems might 
improve the scholastic performance. 
 
   This study would help us to identify the vulnerable children and factors affecting 
overall implication and thus taking necessary steps for management for the same in future. 
 
 
If you take part what will you have to do? 
 
If you agree to take part in the study, you will be required to undergo a psychiatric clinical 
evaluation along with your ward. You will be requested to respond on one standardized 
interview schedules, namely Vanderbilt Assessment Scale and also to assist in filling up 
the socio-demographic and clinical details in a form. You and your ward will undergo an 
interview for assessing mental development using a standard Developmental Screening 
Scale.  The socioeconomic status will also be evaluated with the help of a standardized 
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rating scale. The approximate time for this evaluation would be about 1 and a half hour. 
You or your ward will not be given any extra medications or be subject to any 
newdiagnostic tests or procedure. 
Can you withdraw from the study at any point? 
 
You can withdraw your consent at any point during the process of psychiatric, clinical 
and psychosocial evaluation. However not consenting or withdrawal from the study will 
not hamper the care provided by the hospital to your ward. 
 
 
What will happen if you develop any study related injury? 
 
Since there are no invasive procedures or medications involved, we do not foresee any 
chance of injury due to our process of evaluation. 
 
 
Do you have to make any extra payments for the evaluation? 
 
No extra money will be charged for this evaluation process. 
 
 
What happens after the study is over? 
 
After the evaluation is over and if any psychiatric disorder is diagnosed, then the child will 
be referred to the CAP unit of Department of Psychiatry for further treatment. However the 
cost of treatment will have to be borne by the patient. In this regard no concession will be 
given. 
 
 
Will your personal details be kept confidential? 
 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your medical 
notes may be reviewed by people associated with the study, without your additional 
permission, should you decide to participate in this study. 
 
 
If you have any further questions, please ask Dr.Yogendra Singh, (Telephone/mobile no: 
0416 2284307/ 9585184871, email: dryogendrasingh@yahoo.com 
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APPENDIX-2 
 INFORMATION SHEET-Hindi 
क्रिश्चियन मशे्चडकल कॉलजे,वले्लोर 
मनोरोगश्चवभागएवंन्यूरोलाजीश्चवभाग 
शीषषक :श्चमगीव्याश्चधग्रस्तबच्चोंऔरक्रकशोरोंमें, 
ध्यानआभावसक्रियताश्चवकारकीव्यापकताऔरसाथमजेड़ुेकारकोंकाअध्ययन। 
जानकारीपत्र 
 
ध्यानआभावसक्रियताश्चवकारसेव्याश्चधग्रस्तबच्चोंऔरक्रकशोरोंमेश्चमगीकेसाथऔरउनकेसामाश्चजकजनसांख्यकीयश्चवशे
षताओंकेसाथ-
साथअनेकनैदाश्चनकप्रोफाइलकेप्रसारकोदेखनेकेउदे्दश्यसेआपऔरआपकेवाडषकोएकअध्ययनमंेेभागलेनेकेश्चलयेअनु
रोधक्रकयाजारहाहै।इसमेंश्चमगीकीअवश्चध, श्चमगीशुरुआतकीउम्र, श्चमगीक्रकदवाकीशुरूआत, 
श्चमगीकेउपप्रकारऔरश्चनयंत्रण, 
ध्यानआभावसक्रियताश्चवकारश्चवतरणफैलावजैसेकारकोंकेप्रभावकाअध्ययनकरनाहै।यहज्ञातहकै्रकध्यानआभावस
क्रियताश्चवकारऔरश्चमगीबच्चोंकीअलग-अलगसीखने, 
सामाश्चजकऔरव्यवहाररकश्चवकासपरप्रभावकरसकतेहैं।उम्मीदहैक्रकइनदोनोंकेएकसाथहोनेकेनातेसभीपहलुओंमेंब
च्चोंकेश्चवकासपरअश्चधकसेअश्चधकश्चनश्चहताथषहै।ऐसेबच्चेजोशैक्षश्चणकउपलश्चधधसेदरू, 
जोआनाकानीसक्रियताकेकारणहोसकताहैऔरइनसमस्याओंकाउपयुक्तउपचारसेशैश्चक्षकप्रदशषनमेंसुधारहोसकताहै
। 
 इसअध्ययनसेहमेंकमजोरबच्चोंऔरसमग्रश्चनश्चहताथषकोप्रभाश्चवतकरनेमेंमददश्चमलेगी।इसप्रकारभश्चवष्यमेंउ
नकारकोंकीपहचानकरकेप्रबंधनकेश्चलयेआवश्यककदमउठायेगी। 
यक्रदभागलनेाहैतोआपकोक्याकरनाहोगा? 
यक्रदआपइसअध्ययनमेंभागलेनेकेश्चलयसहमतह,ै 
तोआपकोअपनेवाडषमेंएकमनोरोगनैदाश्चनकमूल्यांकनसगेुजरनाआवश्यकहोजायेगा।आपकोएकमानकीकृमतसाक्षा
त्कारकायषिमअथाषत्टंदकमतइपसजआकलनपैमानेपरआकलनकरनेऔरसामाश्चजकजनसांख्यकीयऔरनैदाश्चनकजा
नकारीकाप्रपत्रभरनेमेंसहायताकेश्चलयेअनुरोधक्रकयाजायेगा।आपकोऔरआपकेवाडषकोएकमानकश्चवकासस्िीननगपै
मानेकाउपयोगमानश्चसकश्चवकासकाआकलनकरनेकेश्चलएएकसाक्षात्कारसगेुजरनाहोगा।सामाश्चजक-
आर्थथकश्चस्थश्चतकीएकमानकीकृतरेटटगस्केलकेमूल्यांकनमेंमददश्चमलेगा।इसमूल्याकंनकेश्चलयेअनुमाश्चनतसमयएकऔ
रआधाघंटाहोगा।आपयाआपकेवाडषकाकोईभीअश्चतररक्तदवाएंयाक्रकसीभीनयेनैदाश्चनकपरीक्षणयाप्रक्रियाओंसेगुजर
नेनहीक्रदयाजायगेा। 
 
क्याआपक्रकसीभीश्चबन्दप े,अध्ययनसवेापसलसेकतहे?ै 
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 आपमनोरोग, 
नैदाश्चनकऔरमनोसामाश्चजकमूल्यांकनकीप्रक्रियाकेदौरानक्रकसीभीश्चबन्दपुरअपनीसहमश्चतवापसलेसकतेहै।हालांक्रक
आपकीनसहमश्चतयवापसीसेअध्ययनमेंआपकेवाडषकेश्चलये, 
अस्पतालद्वारादेखभालप्रदानकीजानेवालीमेंबाधानहींहोगी। 
क्याहोगायक्रदआपकोअध्ययनसम्बश्चन्धतचोटलगजाय? 
 हमारेमूल्याकंनकीप्रक्रियाकेकारणवहाकंोईआिामकप्रक्रियाओंयादवाओं, 
चोटकाकोईभीमौकेकीउम्मीदनहींहै। 
क्यामलू्याकंनकेश्चलयकेोईभीआपकोअश्चतररक्तभगुतानदेनाहोगा?  
 इसमूल्यांकनप्रक्रियाकेश्चलयेअश्चतररक्तपैसेनहींवसूलेजायगेे। 
अध्ययनपरूाहोनकेेबादक्याहोताह?ै 
 मूल्यांकनखत्महोनेकेबादऔरयक्रदक्रकसीभीमनोरोगश्चवकारकाश्चनदानहुआ, 
तबबच्चोकोमनोरोगश्चवभागकीबच्चेऔरक्रकशोरमनोरोगइकाईकोआगेइलाजकरनेकेश्चलयेसंदर्थभतक्रकयाजायगेा।हा
लांक्रकरोगीद्वाराइलाजकाखचषवहनकरनाहोगा।इससम्बन्धमेंकोईररयायतनहींदीजायेंगी। 
आपकेव्यश्चक्तगतश्चववरणगोपनीयरखाजायगेा? 
 इसअध्ययनकेपररणामोंकोमेश्चडकलजनषलमेंप्रकाश्चशतक्रकयाजायगेा, 
लेक्रकनप्रकाशनयापररणामोंकीप्रस्तुश्चतमेंआपकीनामद्वारापहचाननहींकीजायेगी।हालांक्रकआपकेमेश्चडकलनोट्सकी
अध्ययनकेसाथजुड़ेलोगोंद्वाराआपकेअश्चतररक्तअनुमश्चतकेश्चबनासमीक्षाकीजासकतीहैयक्रदआपकइसअध्ययनमेंभाग
लेनेकेश्चलयेश्चनणषयलेतेहै। 
 अगरआपकेपासकोईप्रश्नह,ै तोकृपयासम्पकष करें  -  
डॉ.योगेन्रनसह  ( टेलीफोन/मोबाइलनम्बर :04162284307/9585184871) 
Email: dryogendrasingh@yahoo.com 
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APPENDIX-3 
 INFORMATION SHEET-Bangla 
 
wLªóvb †gwW‡Kj K‡jR †f‡jvi 
g‡bv‡ivM I mœvqy‡ivM wefvM  
 
wk‡ivbvg t g„Mx‡ivM hy³ wkï I eqtmwÜ Kv‡ji †Q‡j I †g‡q‡`i g‡a¨ g‡bv‡hvM NvZwU I nvBcvi A¨vw±wfwU 
‡iv‡Mi cÖv y`f©ve I KviY m¤úwK©Z M‡elYv| 
 
Z_¨vejx 
 
Avcwb Ges Avcbvi ‡Q‡j ev †g‡q‡K GKwU mgx¶v hvi wkï I g„Mx‡ivM m‡½ eqtmwÜKv‡ji g‡bv‡hvM NvUwZ 
nvBcvi A¨vw±wfwUe¨vwa cÖ‡Kvc ÒZv‡Z bvgÓ Ask wb‡Z Aby‡iva Kiv n‡‛Q Ges Zv‡`i wK¬wbKvj †cÖvdvBj, 
Zv‡`i mvgvwRK †W‡gvMÖvwdK •ewkó¨ m‡½ Ges g„Mx‡iv‡Mi mgqKvj, g„Mx‡ivM m~Îcv‡Zi eqm gZ Kvi‡Yi cÖfve 
Aa¨vqb Kivi j‡¶¨ KvR Kiv n‡e g„Mx‡iv‡Mi, e¨eüZ Jla g„Mx‡ivM Ges wLPzwbi wbqš¿Y BZ¨vw`i g‡bv‡hvM 
NvUwZ nvBcvi A¨vw±wfwUe¨vwa m¤^‡Ü GUv Rvbv hvq †h g‡bv‡hvM NvwUZ nvBcvi A¨vw±wfwUe¨vwa Ges g„Mx‡ivM 
c„_K fv‡e wkï‡`i wk¶v, mvgvwRK I AvPiYMZ Dbœqb cÖfvweZ n‡Z cv‡i| GB y`wU GKm‡½ me w`K wkï‡`i 
Dbœ&q‡b e„nËi ms‡k-l Av‡Q e‡j aviYv Kiv n‡‛Q| G ai‡Yi wkï‡`i GKv‡WwgK gvb AR ©‡b e¨_©Zv hv 
AmveavbZv Ges nvBcvi A¨vw±wfwUGes GB mgm¨vi SzwK _v‡K| h_vh_ wPwKrmvq eyw× I Kg©¶gZv e„w× Kivi 
my‡hvM _v‡K| 
 
 GB M‡elYvq Avgv‡`i wkï‡`i Ges mvgwMÖK DbœwZ cÖfvweZ Ki‡Z mvnvh¨ Ki‡e Ges GB fv‡e 
fwel¨‡Z GKB cwiPvjbvi Rb¨ cÖ‡qvRbxq c`‡¶c MÖn‡Y wPwýZ Ki‡Z n‡e| 
 
cÖ t Avcwb Ask wb‡Z cv‡ib I Avcbv‡K wK Ki‡Z n‡e ? 
 
D t Avcwb M‡elYvq Ask wb‡Z m¤§Z n‡j Avcwb Ges Avcbvi †Q‡j/†g‡qi GKwU gvbwmK wK¬wbKvj g~j¨vqb 
Kiv n‡e| Avcbv‡K GKwU B›UviwfD wkwWDj h_v f¨vìviweë A¨v‡mm‡g›U †¯‥‡j mvov Ges GKwU  d‡g©i g‡a¨ 
Av_©-‡W‡gvMÖvwdK Ges wK¬wbKvj Z_¨ c~i‡Yi Rb¨ Aby‡iva Kiv n‡e| Avcwb Ges Avcbvi †Q‡j/†g‡qi gvbwmK 
Dbœqb wba©vi‡Yi GKwU ÷¨vÛvW© †iwUs †¯‥‡ji mvnv‡h¨ g~j¨vqb Kiv n‡e| GB g~j¨vq‡bi Rb¨ AvbygvwbK mgq 
cÖvq 1 Ges GKwU Aa© N›Uv n‡e| Avcbv‡K  ev Avcbvi †Q‡j/†g‡qi †Kv‡bv AwZwi³ Ilya †`Iqv n‡e bv ev 
‡Kvb bZzb WvqMwbw÷K cix¶v Kiv n‡e bv| 
 
cÖ t Avcwb wK †h †Kvb ¯’v‡b Aa¨vqb †_‡K m¤§wZ cÖZ¨vnvi Ki‡Z cvi‡eb ? 
 
D t Avcwb gvbwmK wK¬wbKvj I g‡bvmvgvwRK g~j¨vqb cÖwµqvi mgq †h †Kvb mgq Avcbvi m¤§wZ cÖZ¨vnvi 
Ki‡Z c‡ib| Z‡e Aby‡gv`b bv ev Aa¨vqb †_‡K cÖZ¨vnv‡ii Rb¨ Avcbvi †Q‡j/†g‡qi nvmcvZv‡ji Øviv cÖ`Ë 
hZœ e¨vnZ n‡e bv| 
 
cÖ t GB M‡elYv wK †Kvb AvNvZ m„wó Ki‡e ? 
 
D t †h‡nZz †Kvb ¶wZKviK c×wZ ev Jla RwoZ †bB, ZvB Avgvi g~j¨vqb ev Avgv‡`i cÖwµqvi Kvi‡Y 
AvNv‡Zi †Kv‡bv my‡hvM bvB| 
 
cÖ t Avcbv‡K cix¶v wbix¶vi Rb¨ †Kvb AwZwi³ A_© cÖ`vb Ki‡Z n‡e wK ? 
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D t †Kvb AwZwi³ A_© GB g~j¨vjq cÖwµqvi Rb¨ PvR© Kiv n‡e bv|  
 
cÖ t M‡elYvi ci wK NU‡e ? 
 
D t cix¶v wbix¶vi c‡i hw` †Kv‡bv gvbwmK e¨vwa wbY©q Kiv nq, Zvici mš—vb AviI wPwKrmvi Rb¨ 
mvBwKqvwUª wefv‡Mi CAP BDwbU G cvVv‡bv n‡e| Z‡e wPwKrmvi LiP ‡ivMxi Øviv enb Ki‡Z n‡e| GB welq 
†Kvb Qvo †`Iqv n‡e bv| 
 
cÖ t Avcbvi e¨vw³MZ weeiY †Mvcbxq ivLv n‡e wK ? 
 
D t GB M‡elYvi djvdj GKwU ‡gwWK¨vj Rvb©v‡j cÖKvk Kiv n‡e wKš‘ Avcbvi †Kvb cÖKvkb ev djvdj 
Dc¯’vcbvq bvg D‡j-L Kiv n‡e bv| hvB †nvK, Avcbvi ‡gwWK¨vj †bvU M‡elYvi m‡½ hy³ gvby‡li Øviv, 
Avcbvi AwZwi³ AbygwZ Qvov, ch©v‡jvPbv n‡Z cv‡i hw` Avcwb GB M‡elYvq Ask MÖn‡Yi wm×vš— †bb|  
 
04162284307/9585184871, E-mail - dryogendrasingh@yahoo.comAvcbvi hw` †Kvb cÖkœ 
_v‡K, Zvn‡j Dr. Yogendra wms (†Uwj‡dvb/†gvevBj b¤^‡i †hvMv‡hvM Ki‚b| 
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fpwp];jtf; fy;Y}hp – NtY}h; 
kd ,ay;> euk;gpay; tis 
jiyg;G: typg;G Neha; fz;Ls;s Foe;ij kw;Wk; gUtkile;Njhh;fspy; 
Vw;gLk; ―ftdr;rpjwYk; JWJWg;Gk;”, mjd; guty; epytuKk; mJ 
njhlh;ghd fhuzq;fs; gw;wpa Xh; Ma;T. 
jfty; jhs; 
 e{q;fs; cq;fSila kf;fSk; typg;G NehAld; $ba ftdr; 
rpjwYk; JWJWg;Gk; fz;Ls;s Foe;ij kw;Wk; gUtkile;Njhh;fs; 
kUj;Jt tpguj;JlDk; gpw r%f Gs;sp tguq;fSlDk; ,t;tha;tpy; 
gq;Nfw;f Nfl;Lf;nfhs;sg;gLfpd;w{h;fs;. mNjhL ,t;tha;tpd; Nehf;fk; 
typg;gpd; fhy mstpd; fhuzq;fspd; jd;ik> ftdr; rpjwy;> 
JWJWg;Gf; Nfhshhpd; guty; Mfpait gw;wp mwptjhFk;. 
ftdr;rpjwYk; JWJWg;Gk;> typg;G NehAk; fy;tp fw;gjpYk;> r%f 
tsh;r;rpapYk; Foe;ijfspy; ghjpg;G Vw;gLj;Jnkd mwpag;gl;l 
xd;whFk;. ,t;tpuz;Lk; ,ize;J Foe;ij tsh;r;rpapy; ngWk; 
tpisTfis Vw;gLj;Jk;. ,j;jifa Foe;ijfspd; fy;tpj;juf; FiwTk; 
ftdf; FiwTk; mij k{wpa ,af;fKNk fhuzkhFk;> jFe;j 
kUj;Jtj;jhy; fy;tpj; juk; cauf;$Lk;. 
 ,e;j Ma;T gyt{dkhd Foe;ijfisAk; mjd; KOikahf 
juj;ijAk; fz;L mwpe;J gpd; tUk; kf;fSk; cjtp> nray;gLk; nghUl;Nl 
Vw;wLj;jg;gl;Ls;sJ. 
,e;j Ma;tpy; fye;J nfhs;s xg;Gjy; mspj;jhy; e{q;fs; nra;a 
Ntz;baJ vd;d? 
 Ma;tpy; fye;J nfhs;s tpUg;gk; njhptpj;jhy;> e{q;fSk; cq;fs; 
kf;fSk; kdey fzpg;gpw;F cl;glNtz;Lk;. e{q;fs; Kiwahf;fg;gl;l 
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thz;lh;gpy;]; msT Kiwapd; f{o; Ngl;b fhzg;gl;L r%f epytuk; 
kw;Wk; kUj;Jtk; gs;sp gjpNtl;by; gjpa cjtpnra;ag;gLt{h;fs;. 
e{q;fSk; cq;fs; Foe;ijfSk; kd tsh;r;rpia mwpAk; nghUl;L 
Kiwahd msitapd; f{o; gphpj;J mwpag;gLt{h;fs;. r%f nghUshjhu 
epiyAk; ,jd; %yk; mwpag;gLk;. ,e;j Ma;tpw;fhd Neuk; Vwf;Fiwa 1½ 
kzp Neuk;. ,jw;fhf Nkw;nfhz;L khj;jpiyfNsh my;yJ Gjpa 
Ma;TfSf;Nfh cl;gLj;jg;gl khl;Bh;fs;.  
,t;tha;T Jtq;fpa gpd; ,jdpd;W tpyf ,aYkh? 
 ,t;tha;tpd; kd kUj;Jt kw;Wk; cstpay; fzpg;gpd; NghJ 
ve;Neuj;jpYk; ,jdpd;W tpyfpf; nfhs;syhk;. tpyFtjhdhy; cq;fs; 
tof;fkhd kUj;Jt rpfpr;irapy; cq;fSf;F vt;tpj khWjYk; 
Vw;gLtjw;fpy;iy.  
clk;ig Gz;gLj;Jk; Ma;T KiwfSf;F cl;gLj;jg;gLt{h;fsh? 
 ,e;j Ma;T Kiwfspy; clk;ig fhag;gLj;Jk; kUj;JtKiwfs; 
VJk; ,y;iy. 
,e;j Ma;tpw;fhf Nkw;nfhz;L gzk; Njitg;gLkh? 
 ,jw;fhf Nkw;nfhz;L gzk; nfhLf;f Ntz;ba mtrpak; ,y;iy. 
Ma;T Kbtile;j gpd; vd;d epfoyhk;? 
 Ma;T Kbe;J Neha; fz;lwpe;jgpd; cq;fs; Foe;ij> kw;Wk; 
gUtkile;j Foe;ijfspd; kdey kUj;Jtg; gphptpw;F Nkw;gb kUj;Jt 
,jo;fspy; gpuRhpf;fg;gLk;. Mdhy; cq;fs; ngah; ve;j ,jo;fspNyh 
tpsf;f ciwfspNyh fhl;lg;gLtjpy;iy. ,Ug;gpDk; ,ij Ma;tpy; 
gq;Nfw;Nghh;fshy; cq;fSila $Ljy; mDkjpapd;wp cq;fSila 
kUj;Jt tpguq;fs; ,t;tha;tpy; gq;Nfw;f mDkjp je;jgpd; 
ghpr{ypf;fg;gLk;. 
Nkw;nfhz;L tpguq;fSf;F Dr. NahNfe;jpu rpq;  
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(njhiyNgrp /  ifNgrp vz;- 0416-2284307/  9585184871) 
kpd; mQ;ry; : dryogendrasingh@yahoo.com 
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APPENDIX-5 
Pro Forma for collecting data 
Serial No:__________________ 
 
Socio-demographic and Clinical Data Sheet 
 
Name:______________ ( initials)      Hospital No: 
______________________ 
 
 
 
Date of Birth: __ __/____/_________            Age: ____________Years 
_______Months 
 
 
 
Sex:____ Religion: ___________ Mother Tongue:_______________  
SES:__________ 
 
 _____ 
 
Informant (relationship to patient): 
 
 
I. Patient Related Factors 
 
Perinatal History:  
 Term: Full term/ Preterm/ Post term 
 Duration of Labour: Normal/Prolonged  
 Type of Delivery: Normal/Instrumental/Operation/Not Known 
 Abnormal presentation: Yes/No 
 Low Birth Weight: Yes/No 
 Birth Asphyxia: Yes/No 
 Hypoxic Ischemic Encephalopathy: Yes/No 
 Neonatal Hypoglycemia: Yes/No 
 Sepsis: Yes/No 
 Neonatal Jaundice: Yes/No 
 
Developmental Milestones: 
Current academic standard: 
Academic Performance: 
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I.Q: 
 
 
II. Epilepsy Related Factors 
 
 Age of onset of seizure: 
 Age at diagnosis: 
 Duration of Disease in Days/Months/Years: 
 Seizure Semiology as per ILAE: 
 Seizure Syndrome as per ILAE: 
 EEG Report (past and latest): 
 
 
 MRI/CT Scan: 
 
 
 Anti-epileptic medication used in last 6 months: (drug /dosage)   
1.  
2.  
3.  
4.  
 Current anti-epileptic medication and dosage: 
1. 
2. 
3. 
4. 
5. 
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 Currently Seizure controlled: Yes/ No 
Specify: Seizure frequency: 
              Last clinical seizure (Date/Duration): 
 Compliance with AED treatment: poor/good 
 Additional laboratory reports: 
Drug Serum levels:  
 
 
III.ADHD Diagnosis as per ICD-10 Criteria: Present/ Absent 
 Change in ADHD symptoms with AED treatment: Yes/No 
If yes, specify: 
 Taking Attention Deficit Hyperactivity treatment: Yes/No. 
 If yes in above question, then mention drugs used in last 6 months: 
1.  
2.  
 Other Comorbid Psychiatric Disorder: Yes/ No.  
o Specify if yes: 
 Treatment of Comorbid Psychiatric Disorder, if any: Yes/No 
o Specify if yes: 
 Medical Comorbidities: Yes/ No.  
o Specify if yes 
 Treatment of Medical comorbidities, if any: Yes/No 
o Specify if yes 
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IV. Family Factors 
 Type of family: Nuclear/Extended/ Joint 
 Parents: Living together/Separated/Divorced 
 Total No. of family members: 
 No of siblings: 
 Birth order of participant: 
 Family history of attention deficit hyperactivity disorder: Yes/No 
o If yes, specify 
 Family history of Epilepsy: Yes/no 
o If yes, specify 
 Family history of other mental illness in immediate family member: 
Yes/No 
o If yes, specify 
 
 
 
 
 
 
 
 
 
118 
 
 
APPENDIX-6 
Vanderbilt ADHD Parent Assessment Scale- English. 
 
Vanderbilt Assessment Scale—PARENT Informant 
 
Today‘s Date: _________ Child‘s Name: ______________________________Date of Birth: 
________________ 
 
Hospital Number: ________                              Parent‘s Phone Number: 
_____________________________ 
 
Directions: Each rating should be considered in the context of what is 
appropriate for the age of your child. When completing this form, please think 
about your child‘s behaviors in the past 6 months. 
 
 
Is this evaluation based on a time when the 
child was on medication / was not on medication /not sure.  
       
 Symptoms  Never Occasionally Often Very Often  
 1. Does not pay attention to details or makes careless mistakes 0 1 2 3  
  with, for example, homework       
        
 2. Has difficulty keeping attention to what needs to be done 0 1 2 3  
         
 3. 
Does not seem to listen when spoken to 
directly  0 1 2 3  
        
 4. 
Does not follow through when given directions and fails to finish 
activities 0 1 2 3  
  (not due to refusal or failure to understand)       
         
 5. Has difficulty organizing tasks and activities  0 1 2 3  
        
 6. 
Avoids, dislikes, or does not want to start tasks that require 
ongoing 0 1 2 3  
  mental effort       
        
 7. 
Loses things necessary for tasks or activities (toys, assignments, 
pencils, 0 1 2 3  
  or books)       
         
 8. Is easily distracted by noises or other stimuli  0 1 2 3  
         
 9. Is forgetful in daily activities  0 1 2 3  
         
 10. Fidgets with hands or feet or squirms in seat  0 1 2 3  
         
 11. 
Leaves seat when remaining seated is 
expected  0 1 2 3  
        
 12. Runs about or climbs too much when remaining seated is expected 0 1 2 3  
        
 13. Has difficulty playing or beginning quiet play activities 0 1 2 3  
         
 14. 
Is ―on the go‖ or often acts as if ―driven by a 
motor‖  0 1 2 3  
         
 15. Talks too much  0 1 2 3  
        
 16. Blurts out answers before questions have been completed 0 1 2 3  
         
 17. Has difficulty waiting his or her turn  0 1 2 3  
        
 18. Interrupts or intrudes in on others‘ conversations and/or activities 0 1 2 3  
         
 19. Argues with adults  0 1 2 3  
         
 20. Loses temper  0 1 2 3  
        
 21. Actively defies or refuses to go along with adults‘ requests or rules 0 1 2 3  
         
 22. Deliberately annoys people  0 1 2 3  
        
 23. Blames others for his or her mistakes or misbehaviors 0 1 2 3  
         
 24. Is touchy or easily annoyed by others  0 1 2 3  
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 25. Is angry or resentful  0 1 2 3  
         
 26. Is spiteful and wants to get even  0 1 2 3  
         
 27. Bullies, threatens, or intimidates others  0 1 2 3  
         
 28. Starts physical fights  0 1 2 3  
        
 29. Lies to get out of trouble or to avoid obligations (ie,―cons‖ others) 0 1 2 3  
        
 30. Is truant from school (skips school) without permission 0 1 2 3  
         
 31. Is physically cruel to people  0 1 2 3  
         
 32. Has stolen things that have value  0 1 2 3  
 
 
 
 
 
 
 
Symptoms (continued)  
 
 
 
 
 
 
  Never 
 
 
 
 
 
 
Occasionally 
 
 
 
 
 
 
Often 
 
 
 
 
 
 
Very Often  
 33. Deliberately destroys others‘ property  0 1 2 3  
        
 34. 
Has used a weapon that can cause serious harm (bat, knife, 
brick, gun) 0 1 2 3  
         
 35. Is physically cruel to animals  0 1 2 3  
         
 36. Has deliberately set fires to cause damage  0 1 2 3  
         
 37. 
Has broken into someone else‘s home, business, 
or car  0 1 2 3  
         
 38. Has stayed out at night without permission  0 1 2 3  
         
 39. Has run away from home overnight  0 1 2 3  
         
 40. Has forced someone into sexual activity  0 1 2 3  
         
 41. Is fearful, anxious, or worried  0 1 2 3  
         
 42. 
Is afraid to try new things for fear of making 
mistakes  0 1 2 3  
         
 43. Feels worthless or inferior  0 1 2 3  
         
 44. Blames self for problems, feels guilty  0 1 2 3  
       
 45. 
Feels lonely, unwanted, or unloved; complains that ―no one loves him or 
her‖  0 1 2 3  
         
 46. Is sad, unhappy, or depressed  0 1 2 3  
         
 47. Is self-conscious or easily embarrassed  0 1 2 3  
         
  
 
    
Somewha
t   
    Above  of a   
 Performance Excellent Average Average Problem Problematic 
 48. Overall school performance 1 2 3 4 5  
         
 49. Reading 1 2 3 4 5  
         
 50. Writing 1 2 3 4 5  
         
 51. Mathematics 1 2 3 4 5  
         
 52. Relationship with parents 1 2 3 4 5  
         
 53. Relationship with siblings 1 2 3 4 5  
         
 54. Relationship with peers 1 2 3 4 5  
         
 55. Participation in organized activities (eg, teams) 1 2 3 4 5  
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APPENDIX-7 
Vanderbilt ADHD Parent Assessment Scale-Hindi 
 
 
वेंडरश्चबल्टvkdyu iSekus & iSjsUV eq[kfcj 
Today’s Date:___________ Child’s Name:______________________ Date of 
Birth:___________ 
Hospital Number:_____________  Parent’s Phone Number: 
_____________________  
funsZ”k %प्रत्येक रेटटग क्या आपके बच्चे की उम्र के श्चलए उपयुक्त है के संदभष में श्चवचार क्रकया जाना चाश्चहए A 
tc ;g QkeZ iwjk fd;k tk; rks di`;k vius cPpksa ds vrhr ds 6 ekg ds O;ogkj ij le> 
ysaA 
;g ewY;kadu ml vk/kkj ij gS tc cPpk nok ij Fkk@;k nok ij ugha Fkk@श्चनश्चित नहीं gSA 
 y{k.k dHkh 
ugha 
dHkh 
dHkh 
vDlj Ckgqr 
ckj 
1- D;k fooj.k ij /;ku ugha nsrk gS ;k लापरवाहxyfr;ksa 
djrk gS % mnkgj.k esa & x`gdk;Z ij 
0 1 2 3 
2- tc dk;Z djus dh vko”;drk gksrh gS rks D;k /;ku j[kus 
esa dfBukbZ gksrh gSA 
0 1 2 3 
3- lh/kh dgh gq;h ckr lqurk izrhr ugha gksrk gSA 0 1 2 3 
4- fn;s x;s funsZ”k dk ikyu ugha djrk vkSj izfØ;k lekIr 
djus esa vlQy gks tkrk gSA 
0 1 2 3 
5- कायों और गश्चतश्चवश्चधयों के आयोजन में करठनाई gksrh gSA 0 1 2 3 
6- ftl dk;Z esa ekufld iz;kl dh vko”;drk gS mls R;kx 
nsrk gS] ukilUn djrk gS ;k dk;Z “kq: ugha djuk pkgrk 
gSA 
0 1 2 3 
7- dk;Z vkSj izfØ;k djus esa vko”;d phtksa ] dks [kks nsrk gS A 
¼f[kykSuksa] lkSais x;s dk;Z] isfUlysa ;k fdrkcsa½ 
0 1 2 3 
8- D;k “kksj ;k अन्य mRrstukvksa ls ]आसानी स ेfopfyr gksrk gSA 0 1 2 3 
121 
 
 
9 nSfud xfrfof/k;ksa esa HkqyDdM+ gSA 0 1 2 3 
10 lhV esa gkFk ;k iSj NViVkrk ;k ,saBrk gSA 0 1 2 3 
11 tc lhV is csSBs jgus dh mEehn dh trh gS ] rc oks सीट 
छोड़ देता है A 
0 1 2 3 
12 tc lhV is csSBs jgus dh mEehn dh trh gS ] rc oks p<+rk 
;k nkSM+rk gSA 
0 1 2 3 
13 “kkUr [ksy dh xfrfof/k;ksa ds [ksyus esa ;k “kq:vkr esa 
dfBukbZ gksrh gSA 
0 1 2 3 
14 हमेशा सक्रिय jgrk gS ;k vDlj ,ls dk;Z djsa tSls dh ^^eksVj 
lapkfyr gks ^^ 
0 1 2 3 
15 ckrphr cgqr djrk gSA 0 1 2 3 
16 iz”u iwjk djus ds igys gh cd nsrk gSA 0 1 2 3 
17 ckjh dh izrh{kk esa dfBukbZ gksrh gSA 0 1 2 3 
18 nwljksa dh ckrphr ;k izfØ;k esa :dkoV ;k gLr{ksi djrk 
gSA 
0 1 2 3 
19 O;Ldksa ds lkFk rdZ djrk gSA 0 1 2 3 
20 vkik [kks nsrk gSA 0 1 2 3 
21 o;Ldksa ds vuqjks/k ;k fu;eksa dk ikyu ] lfØ;rk ls 
[kkfjt ;k euk dj nsrk gSA 
0 1 2 3 
22 tku cw>dj yksxksa dks rax djrk gSA 0 1 2 3 
23 अपनी गलश्चतयोंऔर दवु्यषवहारके श्चलए दसूरों को दोषी Bgjkrk हैंA 0 1 2 3 
24 Hkkoqd हैं ;k nwljksa ds }kjk vklkuh ls ukjkt gks tkrk gSA  0 1 2 3 
25 D;k og xqLlk ;k vkØks”k es jgrk gSA 0 1 2 3 
26 क्यावks द्वषेी है और बदला लेना चाहता हैA 0 1 2 3 
27 nwljksa dks xq.MkxnhZ] /kedkrk ;k Mjkrk gSA 0 1 2 3 
28 “kkjhfjd >xM+k “kq: djrk gSA 0 1 2 3 
29 dfBukbZ;ksa ls cpus ds fy;s >wB cksyrk gS ;k nkf;Roksa ls 0 1 2 3 
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cprk gSA 
30 fcuk vuqefr Ldwy ls Hkkxrk gSA 0 1 2 3 
31 yksxksa ij “kkjhfjd :i ls Øwj gSA  0 1 2 3 
32 ewY;oku phtsa pqjkrk gSA 0 1 2 3 
33 tku cw>dj nwljksa dh lEifRr u’V djrk gSA  0 1 2 3 
34 xEHkhj uqdlku iSnk djus okys gfFk;kj dk bLrseky fd;k gS 
¼cYyk] pkdw] bZV] cUnwd½ 
0 1 2 3 
35 tkuojksa ij “kkjhfjd :i ls Øwj gSA 0 1 2 3 
36 tku cw>dj vkx yxk dj uqdlku djrk gSA 0 1 2 3 
37 fdlh ds ?kj] व्यवसाय ;k dkj is सेंध yxk;k gS A 0 1 2 3 
38 fcuk vuqefr ds jkr Hkj ckgj jgk 0 1 2 3 
39 ?kj ls iwjh jkr Qjkj jgk 0 1 2 3 
40 fdlh dks ;kSu xfrfof/k ds fy;s etcwj dj fn;kA 0 1 2 3 
41 D;k Hk;Hkhr] mRlqd ;k fpafrr gSA 0 1 2 3 
42 xyfr;ksa ds Mj ls u;h pht djus dk प्रयासनहीं djrk gSA 0 1 2 3 
43 स्वयं dks csdkj ;k fuEu eglwl djrk gSA 0 1 2 3 
44 Lo;a dks leL;kvksa ds fy;s nks’kh ekurk gS तथा nks’kh eglwl 
djrk gSA 
0 1 2 3 
45 vdsyk] vokafNr ;k vfiz; eglwl djrk gS तथा श्चशकायत 
djrk है क्रक dksbZ mldks I;kj ugha djrkA 
0 1 2 3 
46 nq[kh ;k mnkl gSA 0 1 2 3 
47 Lo;a ds izfr ltx gS ;k ljyrk ls “kfeZank gksrk gSA 0 1 2 3 
 
 izn”kZu अश्चत 
उत्कृष्ट 
औसत स ेऊपर vkSlr dqN gn rd 
dh  leL;k 
leL;k iSnk 
djus okys 
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48 dqy feykdj Ldwy dk izn”kZu 1 2 3 4 5 
49 i<+uk 1 2 3 4 5 
50 ys[ku 1 2 3 4 5 
51 xf.kr 1 2 3 4 5 
52 ekrk&firk ds lkFk lEcU/k 1 2 3 4 5 
53 HkkbZ&cgu ds lkFk lEcU/k 1 2 3 4 5 
54 lkfFk;ksa ds lkFk lEcU/k 1 2 3 4 5 
55 laxfBr xfrfof/k;ksa esa Hkkxhnkjh 
¼tSls&Vheksa esa½ 
1 2 3 4 5 
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APPENDIX-8 
Vanderbilt ADHD Parent Assessment Scale –Bangla 
f¨vÛviweë A¨v‡mm‡g›U †¯‹j Dcw ’¯Z AwffveK 
 
AvR‡Ki ZvwiL t ______________ mš—v‡bi bvg t ________________________ R‡b¥i ZvwiL 
_____________ nvmcvZv‡ji msL¨v t _____________ wcZvgvZv‡`i †dvb b¤^i t _________________ 
wb‡`©k t cÖwZwU †iwUs wK Avcbvi wkïi eq‡mi Rb¨ Dchy³ †cÖ¶vc‡U we‡ePbv Ki‡eb| hLb GB dg©wU c~iY Ki‡eb, MZ 
6 gv‡mi g‡a¨ Avcbvi mš—v‡bi AvPiY m¤ú‡K© g‡b K‡i Ki‡eb| 
 
 
GB g~j¨vqb hLb Kiv nq ZLb wkï, Jla Lvw‛Qj / Jl‡ai Dci wQj bv / Rvwb bv 
j¶Y bv K`vwPr cÖqvB Lye cÖvqB 
1. we¯—vwiZ Z‡_¨i cÖwZ  g‡bvms‡hvM bv Kiv ev g‡bvms‡hv‡Mi Afv‡e fyj 
Kiv, D`vniY – evwoi KvR Kivi mgq 
0 1 2     3 
2. wK Ki‡Z n‡e Zv‡Z g‡bvms‡hvM Kiv 0 1 2     3 
3. mivmwi K_v bv ïb‡Z cvIqv  0 1 2     3 
4. wb‡`©k cvj‡b A¶g Ges Kvh©µg mg‡q †kl Ki‡Z e¨_© (e¨_©Zv ev bv 
eyS‡Z cvivi Rb¨ bq) 
0 1 2     3 
5. KvR †MvQv‡Z ev Kvh©µg Ki‡Z Amyweavq civ 0 1 2     3 
6. gvbwmK ms‡hv‡Mi cÖ‡qvRbZv Gwo‡q P‡j ev AcQ›` K‡i 0 1 2     3 
7. Kg© ev Kvh©µg Kivi mg‡q (†Ljbv, GmvBb‡g›U, †cwÝj ev eB cÖ‡qvRbxq 
wKQz nvivq) 
0 1 2     3 
8. mn‡R †Mvjgv‡ji ev Ab¨vb¨ DÏxcbvi Øviv weåvš— nq 0 1 2     3 
9. ‣`bw›`b Kvh©µg fyj Kiv nq 0 1 2     3 
10. nvZ ev cv‡qi m‡½ DmLymvwb ev wm‡U e‡m QUdU Kiv 0 1 2     3 
11. Avmb †Q‡o D‡V hvq hLb Avm‡b Dcweó _vKv Avkv Kiv n‡‛Q 0 1 2     3 
12. hLb Dcweó _vK‡e e‡j Avkv Kiv n‡‛Q ZLb †`․ovq A_ev †e‡q D‡V 0 1 2     3 
13. kvš— †Ljv Kvh©µg Avi¤¢ Ki‡Z ev †Lj‡Z Amywe‡a nIqv 0 1 2     3 
14. Pj‡Z Pj‡Z ev cÖvqB ÒGKwU †gvUi Øviv PvwjZÓ AvPiYKvix Abyfe nIqv 0 1 2     3 
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15. Lye †ekx K_v e‡j 0 1 2     3 
16. cÖkœ m¤úbœ nevi Av‡M DËi w`‡q †`Iqv 0 1 2     3 
17. my‡hv‡Mi Rb¨ A‡c¶v Ki‡Z Amyweav nIqv 0 1 2     3 
18. A‡b¨i K‡_vcK_‡b Ges Kvh©µ‡g evav †`Iqv 0 1 2     3 
19. eo‡`i m‡½ ZK© Kiv 0 1 2     3 
20. ‡gRvR nvivq  0 1 2     3 
21. mwµq fv‡e cÖvßeq¯‥‡`i Aby‡iva ev wbqg m‡½ eivei †h‡Z AivwR nIqv 0 1 2     3 
22. B‛QvK…Zfv‡e gvbyl‡K wei³ Kiv 0 1 2     3 
23. Zvi fyj ev misbehaviors Rb¨ Ab¨‡`i `vqx Kiv 0 1 2     3 
24. Awfgvbx ev mn‡RB Ab¨‡`i Øviv wei³ nq 0 1 2     3 
25. ivM ev wei³ nq 0 1 2     3 
26. wnsmK Ges mewKQz †c‡Z Pvq 0 1 2     3 
27. `wg‡q ivLv ûgwK ev Ab¨‡`i fq †`Lv‡bv 0 1 2     3 
28. kvixwiK gvivgvwi ïi‚ K‡i  0 1 2     3 
29. me‡P‡q ¸i‚Z¡c~Y© ev eva¨evaKZv Gov‡Z (A_©vr ÒKbmÓ Ab¨‡`i) ev 
mgm¨v †_‡K †ei n‡q Avmvi Rb¨ wg‡_¨ ejv  
0 1 2     3 
30. AbygwZ Qvov ¯‥zj †_‡K cvwj‡q hvIqv 0 1 2     3 
31. kvixiK fv‡e gvby‡li Kv‡Q wbôzi nIqv 0 1 2     3 
32. wKQz g~j¨ Av‡Q Ggb wRwbm Pzwi Kiv 0 1 2     3 
33. B‛QvK…Zfv‡e A‡b¨i m¤úwË aŸsm Kiv 0 1 2     3 
34. A ¿¯ hv ¸i‚Zi ¶wZ Kiv‡Z cv‡i (e¨vU, Qzwi, BU, e›`yK) e¨envi Kiv 0 1 2     3 
35. kvixwiK fv‡e cï‡`i cÖwZ wbôzi nq 0 1 2     3 
36. B‛QvK…Z fv‡e Av¸b jvwM‡q ¶wZ Kivi †Póv 0 1 2     3 
37. Ab¨ Kv‡iv evwo, e¨emv, A_ev Mvwo †f‡½ †`Iqv 0 1 2     3 
38. AbygwZ Qvov iv‡Z evB‡i _vKv 0 1 2     3 
39. evwo †_‡K `~‡i ivwÎevm Kiv 0 1 2     3 
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40. ‡h․b Kvh©Kjv‡ci g‡a¨ KvD‡K eva¨ Kiv 0 1 2     3 
41. fxZ DwØMœ ev wPwš—Z 0 1 2     3 
42. fyj Kivi f‡q bZzb wKQz Kivi †Póv Ki‡Z fq cvq 0 1 2     3 
43. wb‡R‡K †QvU g‡b Kiv  0 1 2     3 
44. mgm¨vi Rb¨ wb‡R‡K `vqx Kiv, wb‡R‡K †`vlx g‡b Kiv 0 1 2     3 
45. wbtm½ AevwÃZ ev fvjevmvnxb Abyf~Z nIqv I Awf‡hvM Kiv Ò†KD Zv‡K 
fvjev‡m bvÓ 
0 1 2     3 
46. `ytwLZ AmyLx ev welbœ nq 0 1 2     3 
47. AZ¥m‡PZb ev mn‡R weeªZ nq 0 1 2     3 
 
 
 
Kg©¶gZv Lye fvj fvj Mo fvj wKQz mgm¨v Av‡Q mgm¨vRwbZ 
48. mvwe©K ¯‥zj Kg©¶gZv     1  2    3         4      5 
49. cov     1  2    3         4      5 
50. ‡jLv     1  2    3         4      5 
51. AsK     1  2    3         4      5 
52. evev-gv‡qi m‡½ m¤úK©     1  2    3         4      5 
53. fvB‡ev‡bi mv‡_ m¤úK©     1  2    3         4      5 
54. mnKgx©‡`i m‡½ m¤úK©     1  2    3         4      5 
55. msMwVZ Kvh©µ‡g AskMÖnY (†hgb `j)     1  2    3         4      5 
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APPENDIX-9 
Vanderbilt ADHD Parent Assessment Scale –Tamil 
tz;Nlh;gpspl; kjpg;g{l;bd; - msTNfhiy ngw;Nwhh; jftywpAk;  
,d;iwa ehs; -------- Foe;ijapd; ngah; ---------------gpwe;j Njjp ------------  
kUj;Jtkidapd; vz; ---------- ngw;Nwhh; njhiyNgrp vz;.---------------------- 
jpirfs;: xt;nthU kjpg;g{L cq;fs; Foe;ijapd; taJ nghUj;jkhdJ vd;d 
#oypy;fUjNtz;Lk;. 
,e;j gbtj;ij g+h;j;jp nra;jNghJ fle;j 6 khjq;fspy; cq;fs; Foe;ijapd; elj;ijfs; gw;wp 
Nahrpj;J ghUq;fs;. ,e;j gbtj;jpd; %yk; Neuk;> Foe;ij ftdj;jpy; cs;sjh /  ,y;iyah 
               mwpFwpfs; ,y;iy jw;nrayhf mbf;fb kpfTk; 
mbf;fb 
1. rhpahd tpjj;jpy; ftdk; 
nrYj;Jtjpy;iy tptuq;fSf;F my;yJ 
cUthfpwJ ftdf;Fiwtpdhy; jtWfs; 
mjw;F cjhuzkh> t{l;L ghlk; 
 
  0 
 
   1 
 
   2 
 
   3 
2. rpukk; MdJ ftdj;ij vd;d 
nra;ag;gl Ntz;b cs;sJ. 
 
  0 
 
   1 
 
   2 
 
   3 
3. rhpahd tpjj;jpy; Nfl;f njhpatpy;iy 
Ngrg;gLk; NghJ Neubahf 
 
  0 
 
   1 
 
   2 
 
   3 
4. rhpahd tpjj;jpy; gpd;gw;w nfhLf;Fk; 
topfs; kw;Wk; Njhy;tpfs; Kbf;f 
eltbf;if (,y;iy ,jdhy; 
fhuzq;fs; my;yJ Njhy;tpfs; Ghpe;J 
nfhs;tjw;F 
 
  0 
 
   1 
 
   2 
 
   3 
5. rpukk; Vw;ghL gzpfs; kw;Wk; 
eltbf;iffs; 
 
  0 
 
   1 
 
   2 
 
   3 
6. Njitapy;iy njhlq;f Ntz;ba gzp 
mJ Njitg;gLk; kd Kaw;rp 
 
  0 
 
   1 
 
   2 
 
   3 
7. ,oe;j nghUl;fs; Njtg;gLk; gzp 
my;yJ eltbf;iffs; (nghk;ikfs;> 
gzpfs;> ngd;rpy;fs;> my;yJ 
Gj;jfq;fs;) 
 
  0 
 
   1 
 
   2 
 
   3 
8. vspjhd jpir jpUg;gk; %yk; Fuy;fs;     
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my;yJ kw;w J}z;Ljy;   0    1    2    3 
9. kwjpahdJ jpdrhp eltbf;iffs; MFk;  
  0 
 
   1 
 
   2 
 
   3 
10. mikahj iffs; fhy;fs; nespe;J 
,Uf;ifapy; 
 
  0 
 
   1 
 
   2 
 
   3 
11. ,iyfs;  ,Uf;ifapy; mg;nghOJ 
k{jKs;s ,Uf;if vjph;ghh;f;fg;gLfpwJ 
 
  0 
 
   1 
 
   2 
 
   3 
12. gw;wp  ud;fs; my;yJ NghJ mkh;e;J 
k{jKs;s mjpfkhf Vwpdhh; 
vjph;ghhf;fg;gLfpwJ. 
 
  0 
 
   1 
 
   2 
 
   3 
13. rpukq;fs; tpisahb my;yJ Muk;gj;jpy 
mikjpahd ehlfk; eltbf;iffs; 
 
  0 
 
   1 
 
   2 
 
   3 
14. ―gazj;jpd;” my;yJ mbf;fb Nghy; 
,af;fg;gLfpwJ” nray;gLfpwJ %yk; 
Nkhl;lhh; 
 
  0 
 
   1 
 
   2 
 
   3 
15 Ngr;Rthh;j;ij mjpfkhf  
  0 
 
   1 
 
   2 
 
   3 
16. cswpf; nfhl;bypUf;fpwJ gjpy;fs; Kd; 
Nfs;tpfs; mj;jpl;lk; Kbe;Jtpl;lJ. 
 
  0 
 
   1 
 
   2 
 
   3 
17. rpukk; fhj;jpUg;gJ mth; my;yJ 
jpUk;GtJ 
 
  0 
 
   1 
 
   2 
 
   3 
18. FWf;f{Lfs; my;yJ FWf;fpLfpwJ. 
kw;wth;fs; ciuahly;fs; kw;Wk; /  
my;yJ eltbf;iffs; 
 
  0 
 
   1 
 
   2 
 
   3 
19. thjhLfpwhh;fs; nghpath;fSld;  
  0 
 
   1 
 
   2 
 
   3 
20. ,of;fpwJ epjhdj;ij  
  0 
 
   1 
 
   2 
 
   3 
21. j{tpukhf nghUe;jhj my;yJ 
nghpath;fSld; nry;y kWg;G 
 
  0 
 
   1 
 
   2 
 
   3 
22. Ntz;Lnkd;Nw ntWg;ghh;fs; kf;fi     
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  0    1    2    3 
23. Fw;wk; rhl;Lfpwhh; mtd; my;yJ 
mtSila jtWfis my;yJ jtwhd 
eltbf;iffis 
 
  0 
 
   1 
 
   2 
 
   3 
24. czh;r;rptrg;gl;L my;yJ vspjpy; 
vhpr;ry; miltJ kw;wth;fsplk; 
 
  0 
 
   1 
 
   2 
 
   3 
25. Nfhgk; my;yJ r{w;wk;  
  0 
 
   1 
 
   2 
 
   3 
26. vjpuhspfshYk; kw;Wk; ngw Ntz;Lk; 
$l 
 
  0 
 
   1 
 
   2 
 
   3 
27. ml;^opaq;fis mr;RWj;Jk;> my;yJ 
kpul;l kwwth;fis 
 
  0 
 
   1 
 
   2 
 
   3 
28. njhlq;FfpwJ cly; rz;il  
  0 
 
   1 
 
   2 
 
   3 
29. ngha;ia nfhz;L gpur;ridapy; ,Ue;J 
ntspNaWtJ my;yJ jtph;g;gJ 
flikapy; ,Ue;J (mjhtJ gjf;fk;> 
kw;wth;fs;) 
 
  0 
 
   1 
 
   2 
 
   3 
30. Nrhk;Ngwp mq;fpUe;J gs;spapy; 
(tpl;LtpLfpwJ gs;sp) ,y;iyahk; 
mDkjp 
 
  0 
 
   1 
 
   2 
 
   3 
31. cly;h{jpahf nfh^ukhdth; kf;fSf;F  
  0 
 
   1 
 
   2 
 
   3 
32. jpUlg;gl;l nghUl;fspd; mjd; kjpg;G  
  0 
 
   1 
 
   2 
 
   3 
33. Ntz;Lnkd;Nw mopf;fpd;whd; 
kw;wth;fspd; nrhj;ij 
 
  0 
 
   1 
 
   2 
 
   3 
34. gad;gLj;Jk; xU MAjk; mJ nra;Ak; 
tpisT j{tpu j{q;F (Ngl;> fj;J> nrq;fy;> 
Jg;ghf;fp) 
 
  0 
 
   1 
 
   2 
 
   3 
35. Cly; h{jpahf nfh^ukhdtd; 
kpUfj;jpdplk; 
 
  0 
 
   1 
 
   2 
 
   3 
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36. Ntz;Lnkd;Nw Vw;gLj;Jk; neUg;gpd; 
tpisT Nrjk; 
 
  0 
 
   1 
 
   2 
 
   3 
37. cilf;fg;gl;lNtW xUthpd; t{L 
tzpfk;> my;yJ fhh; 
 
  0 
 
   1 
 
   2 
 
   3 
38. jq;fpdhd; ntspNa me;j ,uT 
,y;iyahk; mDkjp 
 
  0 
 
   1 
 
   2 
 
   3 
39. Xbtpl;lhd; J}uk; ,Ue;J t{l;by;me;j 
KO ,uT 
 
  0 
 
   1 
 
   2 
 
   3 
40. tw;GWj;Jfpd;whd; ghypay; 
nrayghl;bw;F 
 0  1  2  3 
41. gaj;Jld; Mh;tj;Jld; my;yJ 
ftiyg;gLfpwhh;fnsd;W 
 
  0 
 
   1 
 
   2 
 
   3 
42. mr;rk; fhuzkhf Gjpa tp\aq;fis 
me;j mr;rNk cUthf;FNk jtWfis 
 
  0 
 
   1 
 
   2 
 
   3 
43. ,J gad; mw;wJ my;yJ jho;T 
kdg;ghd;ik 
 0  1  2  3 
44. Fw;wk; rhl;Lfpwhh; Ra gpur;ridf;F> Fw;w 
czh;r;rp 
 
  0 
 
   1 
 
   2 
 
   3 
45. jdpahfNth> Njitaw;wNjh my;yJ 
md;G ,y;yhi; Fw;wkhdJ” mJ ,y;iy 
xUtUk; md;G mtd; my;yJ mts; 
 
  0 
 
   1 
 
   2 
 
   3 
46. tUj;jk; kfpo;r;rpaw;w my;yJ kd 
mOj;jj;Jld; 
 
  0 
 
   1 
 
   2 
 
   3 
47. Ra czh;T my;yJ vspjpy; 
mtkhdg;gLjy; 
 
  0 
 
   1 
 
   2 
 
   3 
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epiwNtw;Wjy; Nkd;ik
ahd 
eLj;jukhd ruhrhp nfhQ;rk; 
epr;rakw;w 
 
epr;rakw;w 
48. Xl;L nkhj;j gs;sp 
nray;jpwd; 
1 2 3 4 5 
49. gbj;jy; 1 2 3 4 5 
 
50. vOjy; 1 2 3 4 5 
 
51. fzpjk; 1 2 3 4  
5 
52. cwT ngw;Nwhh; cld; 1 2 3 4  
5 
53. cwT cld; gpwg;GfSld; 1 2 3 4  
5 
54. cwTfs; rf cwtpdUld; 1 2 3 4  
5 
55. gq;fspg;G Vw;ghL 
eltbf;iffs; 
(vLj;Jf;fhl;L mzpfs;) 
1 2 3 4  
5 
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APPENDIX-10 
Consent Form-English 
 
CHRISTIAN MEDICAL COLLEGE, VELLORE 
 
INFORMED CONSENT  
Informed Consent form to participate in a research study  
Study Title: To study prevalence and factors associated with Attention Deficit 
Hyperactivity Disorder in Children and Adolescents with Epilepsy 
Study Number: ____________ 
 
Subject’s Initials: ______    Subject’s Name: ____________________________ 
 
Date of Birth / Age: ___________________________ 
……………………………………………………………………………………………
…  
Child‘s Guardian  
(i) I confirm that I have read and understood the information sheet dated 
____________for the above study and have had the opportunity to ask questions.  
 
(ii) I understand that my ward‘s participation in the study is voluntary and that I am 
free to withdraw it at any time, without giving any reason and without my medical care 
or legal rights being affected.  
 
(iii) I understand that the researchers, the Ethics Committee and the regulatory 
authorities will not need permission to look at my health records both in respect of the 
current study and any further research that may be conducted in relation to it, even if I 
withdraw my consent from the study. I agree to this access. However, I understand that 
my ward‘s identity will not be revealed in any information released to third parties or 
published.  
iv) I agree not to restrict the use of any data or results that arise from this study 
provided such data is used only for scientific purpose(s)   
(v) I agree on my ward‘s behalf to take part in the above study.  
 
Signature (or Thumb impression) of the Guardian. 
 
Date: _____/_____/______ 
Signatory‘s Name: _________________________________   Signature: 
_________________ 
Or 
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Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator‘s Name: _________________________ 
 
 
Signature (or the Thumb impression) of the Witness: 
________________________________ 
 
Date: _____/_____/_______     
 
 
 
 
 
 
 
Name & Address of the Witness: 
________________________________________________ 
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APPENDIX-11 
Consent Form-Hindi 
 
क्रिियन मेश्चडकलकॉलेज,वेल्लोर 
 
अवगत सहमश्चत 
 
एक शोध अध्ययन में भाग लेने के श्चलये सूश्चचत सहमश्चत पत्र 
 
अध्ययन शीषषक - श्चमगी व्याश्चधग्रस्त बच्चों और क्रकशोरों में ध्यान आभाव सक्रियता श्चवकार की व्यापकता और 
साथ म ेजड़ुे कारकों का अध्ययन। 
अध्ययन नम्बर: _________ 
श्चवषय के नाम के पहले अक्षर:____________  श्चवषय का नाम:__________________________ 
जन्म श्चतश्चथ/उम्र:____________ 
................................................................................................................................................. 
बच्चे का अश्चभभावक 
(1) मैंने सूचना सीट, तारीख------------को पढ़ और समझ कर पशु्चष्ट कर श्चलया है क्रक मुझे उपयुषक्त अध्ययन 
और सवाल पूछने का अवसर प्राप्त है। 
(2) मैं समझता हूँ क्रक मेरे वाडष के अध्ययन में भागीदारी स्वैश्चछछक है और मै इस ेक्रकसी भी समय, श्चबना कारण 
बताय वापस लेने को स्वतन्त्र हं । इस तरह करने से श्चचक्रकत्सा देखभाल या मेरे कानूनी अश्चधकार प्रभाश्चवत 
नही होगे। 
(3) मैं समझता हं क्रक शोधकताषओं, काम कर रहे नैश्चतकता सश्चमश्चत और श्चनयामक अश्चधकाररयों को, वतषमान 
अध्ययन और इसके सम्बन्ध में आयोश्चजत क्रकया जा रहा क्रकसी भी आगे का अनुसन्धान,के सम्बन्ध में अपके 
स्वास््य ररकाडष को देखने की अनुमश्चत की जरूरत नहीं होगी, यहाूँ तक क्रक मैं अपनी अध्ययन से सहमश्चत 
वापस ले लंू क्रफर भी । मैं इसका उपयोग करने दने के श्चलये सहमत हूँ । हालांक्रक मैं समझता हूँ क्रक मेरी वाडष 
की कोई भी जानकारी की सचूना तीसरे पाटी य प्रकाशन के श्चलये व्यक्तनहीं होगी। 
(4) मैं इस अध्ययन से श्चनकले क्रकसी जानकारी या पररणाम केउपयोग को प्रश्चतबशं्चधत नहीं करता हूँ यक्रद यह 
डाटा केवल वैज्ञाश्चनक उदे्दश्यों के प्रयोग के श्चलये होंगें। 
(5) मैं उपरोक्त अध्ययन में भाग लेने के श्चलये अपने वाडष की ओरसे सहमत हूँ। 
 
अश्चभभावक के हस्ताक्षर (या अंगूठे का श्चनशान) 
तारीख:_________ 
हस्ताक्षरकताष का नाम:_____________________________हस्ताक्षर:_____________________ 
 या 
 
 
 
 
अन्वेषक के हस्ताक्षर:_____________________ 
तारीख:____________ 
अध्ययन अन्वेषक का नाम:_________________________________ 
 
गवाह के हस्ताक्षर (या अंगूठे का श्चनशान) 
तारीख:_________ 
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हस्ताक्षर:____________________________या 
 
 
हस्ताक्षरकताष का नाम और पता:__________________________________________________ 
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APPENDIX-12 
Consent Form-Bangla 
wLª÷vb †gwW‡Kj K‡jRভেল্লোরে 
 
AewnZ m¤§wZ 
 
AeMZ Kb‡m›U dg© GKwU M‡elYvq Ask MÖn‡Yi Rb¨ ÷vwW wk‡ivbvg wkï Ges g„Mx‡ivM m‡½ eqtmwÜKv‡ji 
e¨vcKZv I g‡bv‡hvM NvUwZ nvBcvi A¨vw±wfwUwWmW©vi m‡½ hy³ welq¸wji cov‡kvbv Ki‡Z ÷vwW msL¨v 
________ 
 
mve‡R‡±i Av`¨¶i t _____ mve‡R‡±i bvg t ________________________  
 
Rb¥ / eqm ZvwiL _____________________ 
............................................................................................................ 
 
wkïi AwffveK, 
 
1| Avwg wbwðZ ‡h Avwg c‡owQ Ges Dc‡i mgx¶vi ___________ Z_¨ kxU ey‡SwQ Ges cÖkœ wRÁvmv Kivi 
Avwg my‡hvM †c‡qwQ| 
 
2| Avwg SzS‡Z †c‡iwQ M‡elYvq Avgvi AskMÖnY †¯^‛Qv‡mevg~jK Ges †h Avwg †Kvb KviY QvovB Ges wPwKrmv 
ev AvBbMZ AwaKvi cÖfvweZ bv K‡i Avwg Avgvi AbygwZ cÖZ¨vnvi Ki‡Z cvwi| 
 
3| Avwg eyS‡Z †c‡iwQ †h M‡elK, c„ô‡cvl‡Ki c‡¶ KvR Ki‡Q| bxwZkv¯¿ KwgwU I wbqš¿K KZ©„c‡¶i eZ©gvb 
M‡elYvq Ges †KvbI M‡elYv GwU m¤úK© cwiPvwjZ n‡Z cv‡i| Avgvi ¯^v¯’¨ †iK‡W©i AbygwZi cÖ‡qvRb n‡e 
bv| GgbwK hw` Avwg M‡elYv †_‡K Avgvi m¤§wZ cÖZ¨vnvi Kwi Avwg GB A¨v‡·m Ki‡Z m¤§wZ w`jvg| 
hvB‡nvK Avwg eyS‡Z cvwi †h Avgvi Iqv‡W© cwiPq Z_¨ Z…Zxq c‡¶i Kv‡Q cÖKvwkZ Kiv n‡e bv| 
 
4| Avwg GB Z_¨ †Kej ‣eÁvwbK D‡Ïk¨ e¨env‡ii m¤§wZ w`jvg| 
 
5| Avwg Avgvi †Q‡j/†g‡qi n‡q DcwiD³ M‡elYvi Ask MÖn‡Y m¤§wZ Rvbvw‛Q| 
 
Awffve‡Ki ¯^v¶i (wUc mB)  
 
ZvwiL t  
 
¯^v¶iKvixi bvg .............................................................. ¯^v¶i; 
 
ev 
 
 
 
M‡elK, †h e¨vL¨v K‡i‡Qb 
 
¯^v¶i :   
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Wt †hv‡M› ª` wms                                               ZvwiL 
 
 
 
 
mv¶x ¯^v¶i...................................                    ev 
 
ZvwiL t  
 
¯^v¶iKvixi bvg : 
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APPENDIX-13 
Consent Form-Tamil 
fpwp];Jt kUj;Jtf; fy;Y}hp> NtY}h; 
 
mwptpg;G gbtk; 
mwptpg;G gbtk; gq;fspg;G Muha;r;rp gbg;G 
 
gbg;gpd; jiyg;G: Kiwahd mDkjp tbtk; xU Ma;T gq;Nfw;f Ma;T 
jiyg;G fhy;-if typg;G Foe;ijfs; kw;Wk; tsh; ,sk; gUtj;jpdUf;F 
ftdf;FiwT mjpfhpf;f NfhshW njhlh;Gila Neha;j;jhf;fKk; 
fhuzpfs; gbf;f. 
 
gbg;G vz; --------- 
ghlj;jpd; Kjy; -------   ghlj;jpd; ngah; -------- 
gpwe;j Njjp /  taJ>   ----------- 
------------------------------------------------- 
Foe;ijfs; fhg;ghsh; 
 
1. ehd; cWjpahf ehd; gbj;J kw;Wk; Ghpe;J nfhz;l ,e;j ehs; Njjp --- 
,jd; %ykhf gbg;G kw;Wk; tha;g;Gfs; Nfs;tpfs; Nfl;gjw;F. 
 
2. ehd; Ghpe;J nfhz;Nld; mjhtJ vd;Dila gphpT gq;fspf;fpd;wJ 
,e;j gbg;gpy; tpUg;gj;Jld; kw;Wk; mJkl;Lky;y ehd; ,ytrkhf 
vg;NghJ Ntz;LkhdhYk; tpilngw;W nfhs;syhk; ve;j NeuKk;> 
ve;jtpj fhuzk; kw;Wk; ve;jtpj kUj;Jt ftdKk; my;yJ rl;l chpik 
ghjpg;G. 
 
3. ehd; Ghpe;J nfhz;l Muha;r;rp NtW Ntiyfs; gpzpahdapapd; 
nghUl;L xOf;fkhd FO kw;Wk; jpl;lk; nra;a chpikahsh;fs; 
mth;fSf;F ve;j tpj mDkjpAk; ghh;g;gjw;F vd;Dila cly; gjpT> 
,uz;Lk; epYitapy; cs;s gbg;G kw;Wk; VjhtJ Nth; Muha;r;rp mJ 
Ntz;Lkhdhy; elj;jp njhlh;G nfhs;syhk; mg;NghJ ehd; jpUk;gp 
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ngw;W nfhs;s cld;ghLld; ngw;W nfhs;s cjTk; gbg;G ehd; xj;J!  
nfhs;fpd;Nwd;. ,ij ,Ug;gpDk; ehd; Ghpe;J nfhz;L vd;Dila 
gphpT’ milahsj ;ij vg;nghOJk; njhptpf;f khl;Nld. ve;j 
tptuj;ijAk; %d;whtJ eghplk; njhptpf;fkhl;Nld;. my;yJ 
ntspg;gLj;jkhl;Nld 
 
4. ehd; Vw;Wf; nfhs;fpd;Nwd; ve;j tpj jil vd;Dila tptuq;fs; 
gad;gLj;Jk; tptuq;fs; my;yJ KbTfs; mJ ve;jtpj tptuq;fs; 
mwptpay; g+h;tkhf kl;LNk Nkw;nfhs;sg;gLk;. 
 
5. ehd; Vw;Wf;nfhs;fpd;Nwd; ve;j tpj jil vd;Dila gphptpd; gb 
Nkw;$wpa gbg;gpy; <LgLNtd;. 
ifnahg;gk; (my;yJ) ngUtpuy; cwtpdh; /  rl;lg+h;tkhf 
VwWf;nfhs;sg;gLfpd;Nwd;.  
 
Njjp ---/ ----/ ---- 
ifnahg;gk;eghpd; ngah; ----------  ifnahg;gk; 
my;yJ   
 
 
 
Gyd; tprhuidahshpd; ifnahg;gk;: 
Njjp: 
Gyd; tprhuidahshpd; ngah; 
 
gpujpepjpahd rhl;rp 
 
Njjp ----/ ------/ ----- 
ifnahg;gk; eghpd; ngah; /  if tpuy; Nuif 
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APPENDIX-14 
Child Assent-English 
CHILD ASSENT FORM 
 
STUDY TITLE:Prevalence and factors associated with Attention Deficit 
Hyperactivity Disorder in Children and Adolescents with Epilepsy. 
 
I am Dr. Yogendra Singh from Department of Psychiatry – CMC Vellore. I am doing a 
study to figure out the prevalence of Attention Deficit Hyperactivity Disorder (ADHD) 
in children and adolescents with epilepsy and the associated factors 
 
For this research, we will ask you some questions about yourself and problems related 
to your behavior. We will keep all your answers private, and will not show them to 
your family members or teachers. Only people who are working on the study will see 
them. 
  
No additional injections or operations would be required for this study. 
 
 
By participating in this study you will not get any extra benefit in terms of the cost of 
your treatment. However if we diagnose any problems, we would give you the option 
of treatment from us. 
  
You should know that: 
 
• You do not have to be in this study if you do not want to. You won‘t get into any 
trouble with the hospital, teacher, or the school if you say no. 
 
• You may stop being in the study at any time. If there is a question you don‘t want to 
answer, just leave it blank. 
 
• Your parent(s)/guardian(s) were asked if it is OK for you to be in this study. Even if 
they say it‘s OK, it is still your choice whether or not to take part. 
 
• You can ask any questions you have, now or later. If you think of a question later, you 
or your parents can contact me at the following phone number or email address. 
 
Sign this form only if you:  
• have understood what you will be doing for this study, 
 
• have had all your questions answered, 
 
• have talked to your parent(s)/legal guardian about this project, and 
 
• agree to take part in this research 
 
141 
 
 
______________________________________________________________________
_ 
Your Signature Printed Name          Date 
______________________________________  
Name of Parent(s) or Legal Guardian(s)  
______________________________________________________________________
_ 
Researcher explaining study   
Signature                               Dr. Yogendra Singh           Date 
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APPENDIX-15 
Child Assent-Hindi 
क्रिियन मेश्चडकलकॉलेज,वेल्लोर 
 
बचे्च स्वीकृश्चत प्रपत्र 
 
अध्ययन शीषषक : श्चमगी व्याश्चधग्रस्त बच्चों और क्रकशोरों में ध्यान आभाव सक्रियता श्चवकार की 
व्यापकता और साथ म ेजड़ुे कारकों का अध्ययन। 
 
मैं डॉ.योगेन्र नसह मनोरोग श्चवभाग- क्रिियन मेश्चडकलकॉलेज, वेल्लोर से हूँ। मैं श्चमगी व्याश्चधग्रस्त 
बच्चों और क्रकशोरों में ध्यान आभाव सक्रियता श्चवकार की व्यापकता और साथ म े जुड़े कारकों का 
अध्ययन कर रहा ह। 
 
इस शोध के श्चलए हम आपको कुछ सवाल अपने आपको और अपने व्यवहार से सबंंश्चधत समस्याओं के 
बारे में पूछने होगा। हमें सभी आपके उत्तर गपु्त रखगे और उन्हें आपके पररवार के सदस्यों य श्चशक्षकों 
को नहीं क्रदखायेंगे। केवल जो लोग अध्ययन पर कायष कर रहें हैं, उन्हें क्रदखायेंगे।  
 
इस अध्ययन के श्चलये कोई अश्चतररक्त इंजेक्शन या कायषवाही की आवश्यकता नहीं है।  
 
इस अध्ययन में भाग लेने में, उपचार के लागत के मामले में कोई अश्चतररक्त छूट नहीं श्चमलगेी। जबक्रक 
यक्रद हम क्रकसी समस्या का श्चनदान करें, आप हमसे उपचार का श्चवकल्प लेगे। 
 
आपको पता होना चाश्चहए क्रक  
o यक्रद आप अध्ययन में भाग लेना नहीं चाहते है, तो आप इनकार कर सकते है। यक्रद 
आप इनकार करते हैं, तो आपको अस्पताल, श्चशक्षक य स्कूल म े क्रकसी भी मसुीबत 
का समन नहीं होगा। 
o आप क्रकसी समय भी अध्ययन बन्द कर सकते हैं I यक्रद आप क्रकसी सवाल का जवाब 
नहीं देना चाहते है तो बस इस ेखाली छोड़ दें।  
o आपके माता-श्चपता/अश्चभभावक इस अध्ययन की अनुमश्चत पूछा गया है। भले ही वे 
हाूँ कहते हैं इसमें भाग लेने का चुनाव आप करेग।े 
o आप अभी या बाद में कोई भी प्रश्न पूछ सकते ह।ै यक्रदआप कोई प्रश्न के बारे मे बाद 
में सोचते हो, तुम या तुम्हारे माता-श्चपता फोन नं0 या ईमेल से सम्पकष  कर सकते हैं। 
 
हस्ताक्षर तभी करे जब आप: 
o समझ गय ेहैं तुम इस अध्ययन में क्या करोंगे 
o तुम्हारे सभी प्रश्नों के उत्तर श्चमल गय ेहै। 
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o तुम अपने माता-श्चपता/अश्चभभावक से इस पररयोजना के बारे में बात कर चुके हैं 
और  
o इस शोध में भाग लेने के श्चलये सहमत हैं।  
 
 
 
___________________________________________________________________ 
अपके हस्ताक्षर                    मुक्ररत नाम                      तारीख 
 
 
_________________________________ 
अपके माता-श्चपता/अश्चभभावक का नाम: 
 
 
___________________________________________________________________ 
अध्ययन समझाने वाला शोधकताष 
 
 
हस्ताक्षरडॉ योगेन्र नसह    तारीख 
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APPENDIX-16 
Child Assent-Bangla 
AbygwZ cÎ 
 
wk‡ivbvg t g„Mx‡ivM hy³ wkï I eqtmwÜ Kv‡ji †Q‡j I †g‡q‡`i g‡a¨ g‡bv‡hvM NvZwU I nvBcvi A¨vw±wfwU ‡iv‡Mi 
cÖv`yf©ve I KviY m¤úwK©Z M‡elYv| 
 
wm Gg wm †f‡jv‡ii Avwg mvBwKqvwUª wefv‡Mi Wvt †hv‡M›`ª wms| Avwg GKwU M‡elYv KiwQ wkï I g„Mx‡ivM m‡½ 
eqtmwÜKv‡ji Ges mswk-ó wbqg‡K (ADHD) g‡bv‡hvM NvUwZ nvBcvi A¨vw±wfwUwWmW©v‡ii cÖ‡Kvc wb‡q| 
 
GB M‡elYvi Rb¨ Avgiv Avcbv‡K Avcbvi wb‡Ri Ges Avcbvi AvPi‡Yi mv‡_ m¤úwK©Z mgm¨v m¤ú‡K© wKQz cÖkœ wRÁvmv 
Kie| Avgiv Avcbvi me DËi †Mvcb ivLe Ges Zv‡`i Avcbvi cwiev‡ii m`m¨ ev wk¶K‡K †`Lv‡Z n‡e bv| ïay gvbyl 
hviv M‡elYv Ki‡Qb Zv‡`i †`Lv‡Z n‡e| 
 
‡Kvb AwZwi³ Bb‡RKkbI Ac‡ikb GB M‡elYvi Rb¨ cÖ‡qvRb n‡e bv| 
GB M‡elYvq Ask MÖnY Kivi gva¨‡g Avcwb Avcbvi wPwKrmvi LiP cwi‡cÖw¶‡Z †Kvb AwZwi³ myweav cv‡eb bv| Z‡e 
Avgiv hw` †Kvb mgm¨v wbY©q Kvi, Z‡e Avgiv Avcbv‡K Avgv‡`i KvQ †_‡K wPwKrmvi civgk© w`‡Z cvie| 
 
Avcbvi Rvbv DwPr t 
Avcwb PvB‡jB GB M‡elYv n‡e bB‡j n‡e bv| Avcbv‡K nmwcUvj, wk¶K ev ¯‥z‡ji m‡½ †Kvb Sv‡gjv‡Z co‡Z n‡e bv| 
 
Avcwb †h †Kvb mg‡q M‡elYv eÜ Ki‡Z cv‡ib| hw` †Kvb cÖ‡kœi DËi w`‡Z bv Pvb, ïay GUv duvKv RvqMv ivLyb| Avcbvi 
wcZvgvZv‡`i / AwffveK‡`i AbygwZ †bIqv n‡e Ges Zvi c‡iI Avcbvi AwaKvi _vK‡e GB M‡elYvq AbygwZ 
cÖZ¨vnv‡ii| 
 
hw` Avcbvi †Kvb cÖkœ _v‡K Avcwb wRÁvmv Ki‡Z c‡ib| GLb ev c‡i| Avcwb c‡i hw` cÖkœ g‡b K‡ib Zvn‡j Avcwb ev 
Avcbvi evev Avgv‡K wbgœwjwLZ †dvb b¤^i ev B‡gj wVKvbvq †hvMv‡hvM Ki‡Z cv‡ib| 
 
Avcwb GB dg© mvBb Ki‚b, ïaygvÎ ZLbB hw` Ñ 
 
Avcwb GB M‡elYvi Rb¨ wK KvR Kiv n‡e eyS‡Z cv‡ib 
 
Avcbvi me cÖ‡kœi DËi cvb 
 
Avcbvi evev-gv / AvBbMZ Awffve‡Ki mv‡_ GB cÖKí wb‡q K_v e‡j‡Qb 
 
GB M‡elYvi Ask wb‡Z m¤§Z n‡q‡Qb 
 
 
      Avcbvi ¯^v¶i             gyw`ªZ bvg       ZvwiL 
 
 
AwffveK A_ev AvBbMZ AwffveK‡`i bvg:  
 
M‡elK,  †h e¨vL¨v K‡i‡Qb 
¯^v¶i                              Wt †hv‡M›`ª wms                            ZvwiL 
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APPENDIX-17 
Child Assent-Tamil 
 
Foe;ij xg;Gjy; gbtk; 
gbg;gpd; jiyg;G: Kiwahd mDkjp tbtk; xU Ma;T gq;Nfw;f Ma;T 
jiyg;G fhy;-if typg;G Foe;ijfs; kw;Wk; tsh; ,sk; gUtj;jpdUf;F 
ftdf;FiwT mjpfhpf;f NfhshW njhlh;Gila Neha;j;jhf;fKk; 
fhuzpfs; gbf;f. 
 ehd; lhf;lh; NahNfe;jpurpq; vd;Dila Jiw kdey kw;Wk; 
euk;gpay; Jiw rp.vk;.rp NtY}h; ehd; vd;Dila gbg;gpd; njhlh;ghd 
jiyg;G Neha;j;jhf;fKk; Foe;ijfs; kw;Wk; typg;G tsh; ,dk; 
gUtj;jpdUf;F ftdj;ij mjpapaf;ff; NfhshW njhlh;ghd fhuzpfs; 
gw;wpa Xh; Ma;T 
 ,e;j Muha;r;rpapy; ehq;fs; rpy tpdhf;fis cq;fsplk; 
njhLg;Nghk; kw;Wk; rpf;fypd; tpisthd cq;fs; nray;ghL. ehq;fs; 
cq;fSila vy;yh gjpy;fisAk; ghJfhg;ghf> kw;Wk; ,ij ahh; ,lk; 
fhz;gpf;fkhl;Nlhk;. cq;fSila FLk;gj;jpdhplKk;> my;yJ 
MrphpahplNkh. 
 ,y;iy $Ljyhd CrpNah my;yJ mWitrpfpr;irNah ,jw;F 
Njitg;gLk;. ,e;j gbg;gpy; ,e;j gq;Nfw;gpd; rk;ke;jkhd gbg;gpd; 
cq;fSf;F ve;j $Ljyhd kjpg;G ,e;j gUtj;jpd; ve;j tpj $Ljyhd 
njhifahd rpfpr;ir mspf;fg;glhJ ,Ug;gpDk; ehq;fs; mwpe;Njhk; 
VjhtJ gpur;rid> ehq;fs; cq;fSf;F tha;g;Gf;fhd rpfpr;irfis 
mspg;Nghk;. 
e{q;fs; njhpe;J nfhs;s Ntz;baJ: 
 e{q;fs; ,e;j ghlg;gphptpy; jhd; ,Uf;f Ntz;Lk; vd;W ,y;iy. 
cq;fSf;F tpUg;gk; ,Ue;jhy; e{q;fs; ve;j tpj njhe;juTk; 
nfhLf;f $lhJ kUj;Jtkidapy;> Mrphpah;fs;> my;yJ gs;spfs; 
,y;iy vd;W nrhy;y. 
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 e{q;fs; epWj;jpf; nfhs;syhk; gbg;gpy; ,Ue;J ve;NeuKk; 
cq;fSf;F VjhtJ Nfs;tpfSf;F tpilaspf;f> tpUg;gk; ,y;iy 
vd;why; mg;NghJ tpl;L tpLq;fs; ntWikahf. 
 cq;fs; ngw;Nwhh;(fs;) /  ghJfhg;ghsh;;(fs;) cq;fsplk; rhp vd;W 
cq;fis ,e;j gbg;ig gw;wp ,Ue;jhYk; ,jd; gpd;G $l’ 
nrhy;yyhk; rhp> vy;yhk; cq;fSila tpUg;gj;jpd; gb Ntz;Lk; 
vd;why; vLj;J nfhs;syhk;. ,y;iy vd;why; tpl;L tplyhk;. 
 e{q;fs; ve;j tpj Nfs;tpfSk; e{q;fs; ,g;nghOJk; ,jd;gpd;G 
Nfl;fyhk;. e{q;fs; rpe;jpj;J gpd;G e{q;fs; my;yJ> cq;fs; 
ngw;Nwhh; njhlh;G nfhs;s Fwpg;gpl;l njhiyNgrp my;yJ kpd; 
mQ;rypy; njhlh;G nfhs;syhk;. 
 
 
ifnahg;gk; ,lTk; ,e;j gbtj;jpy; e{q;fs; 
 e{q;fs; Ghpe;J nfhz;Bh;fsh vd;d nra;a Ntz;Lk; ,e;j 
gbg;gpd; %yk;. 
 e{q;fs; vy;yh tpj Nfs;tpfSf;Fk; gjpy; mspj;J tpl;Bh;fsh. 
 e{q;fs; cq;fs; ngw;Nwhh; ,lk; (my;yJ) /  cWjpg+h;tkhd 
fhg;ghsh; ,ij gw;wp nray;jpl;lk;> kw;Wk; 
 cWjpg;g+h;tkhf Vw;Wf; nfhs;fpd;Nwd;. ,e;j Muha;r;rpia 
 
cq;fs; ifnahg;gk;;    mr;rpd; ngah;        Njjp 
 
 
ngw;Nwhh;fspd; ngah; my;yJ cWjpg+h;tkhd fhg;ghsh;(fs;) 
 
 
 
Muha;r;rp tpthpg;G gbg;G> 
 
ifnahg;gk; lhf;lh;. NahNfe;jpurpq;      Njjp 
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APPENDIX-18 
Data View 
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APPENDIX-19 
Data View 
 
 
